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Abstract 
Methods for generating surface-immobilized biomolecular patterns and gradients have 
provided invaluable insight into the molecular basis of numerous complex biological processes. 
Herein, we describe the development of a general, photochemical method for creating 
biointerface substrates presenting single- and multi-component biomolecular patterns and 
gradients.  In our approach, the generation of a light density gradient across a photoactive 
benzophenone monolayer on glass results in covalent attachment of solution-phase biomolecules 
onto the surface. This simple, direct and molecularly general approach was used to generate 
surface-immobilized biomolecular gradient substrates for proof-of-principle biomolecular 
photopatterning demonstrations, as well as investigations of multi-parameter cell-substrate 
interactions and fundamental leukocyte biology studies. Substrates tailored to present P-selectin 
or E-selectin, which are proteins expressed on the inflamed endothelium, were applied to flow 
assays with neutrophils isolated from whole blood for investigating the effects of bromelain, an 
alternative anti-inflammatory treatment, on neutrophil recruitment in vitro under conditions of 
physiological shear stress. Beyond applications in leukocyte biology, this methodology for 
biomolecular substrate generation can serve as an enabling tool for investigating the molecular 
basis of cell migration and polarization in response to immobilized proteins, and for 
systematically addressing the combined effects of multiple stimuli, such as immobilized 
biomolecule density, mechanical cues, and shear stress on cell behavior.  
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Chapter 1 
 
Introduction and Background 
 
Cellular adhesive microenvironments are enormously complex and dynamic. The 
interplay between the density and spatial distribution of many distinct biomolecules determines 
the response and behavior of cells in vivo. To better understand the nature of these complex 
physiological processes that consist of interfacial recognition events, scientists have utilized 
expertise in molecular synthesis and design to control and influence the behavior of cells,1 
resulting in well-defined surfaces presenting biologically relevant ligands at distinct spatial 
locations.3 Methods for the generation of substrates presenting biomolecules in a spatially 
controlled manner are therefore enabling tools for applications in fundamental biological studies, 
as well as biosensor systems, microarray technologies, and biointerface science. My doctoral 
research has focused on the development of a general method for creating single- and multi-
component biomolecular pattern and gradient substrates for applications in leukocyte biology. 
The biomolecular patterns and gradients and their subsequent biological applications presented 
herein demonstrate the potential of the developed biointerface methodology to help shed light on 
the mechanism by which the activated endothelium recruits leukocytes to the blood vessel wall 
during the first steps of the inflammatory response (Figure 1.1).   
This introductory chapter consists of an overview of the various components that make 
up this interdisciplinary work. An overview of the different strategies that have been developed 
to generate biomolecular substrates is presented, including the simple, direct and molecularly 
general approach that utilizes the photoactive properties of benzophenone (BP) to generate 
quantifiable surface-immobilized biomolecular patterns and gradients. Next, a brief review of the 
current molecular understanding of the process of leukocyte recruitment and inflammation is 
presented, including an introduction to bromelain, a natural anti-inflammatory therapeutic, which 
is the focus the biological applications of the described biomolecular substrate generation 
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methodology. Finally, the various in vivo and in vitro approaches that have been taken to study 
leukocyte recruitment is discussed, and a case is made for why the BP-mediated biomolecular 
substrate generation methodology is an enabling tool for investigating the molecular basis of 
leukocyte recruitment and investigating the potential mechanisms for bromelain’s anti-
inflammatory activity.  
 
 
 
 
 
 
 
 
 
 
1.1 Strategies for generating surface-immobilized biomolecular patterns and gradients 
Numerous methods have been previously reported for the generation of substrates 
presenting immobilized biomolecules. These include the use of microfluidics followed by 
surface attachment,4 electrochemical desorption of self-assembled monolayers on gold,5 
photochemical surface deprotection to reveal reactive functional groups,6 and diffusion-guided  
surface adsorption.7 Biomolecular gradients generated with these methods have been 
implemented in a variety of applications including  biointerface science,8 microarray 
technology,9 biosensors,10 microfluidics/point-of-care applications,11 and nanotechnology.12 
Tools for generating substrates with immobilized biomolecules have been rapidly developing 
 
Figure 1.1  Schematic representation of the leukocyte adhesion cascade. Cytokine-activated 
endothelial cells present selectins, chemokines, and intercellular adhesion molecules (ICAMs) 
that enable leukocyte capture, rolling, and firm adhesion. Adapted from reference.2 
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due to a growing interest in exercising spatio-temporal control over protein patterns,1 
characterizing immobilized protein site density for quantitative biointerface studies,13 and 
generating substrates presenting multiple ligands to model complex physiological environments 
and perform multi-parameter biological assays.4a,5,14  
The ideal gradient generation approach is one that is simple, molecularly general, 
quantifiable, and easily extendable to create substrates with higher levels of biomolecular 
substrate complexity. Yet every gradient generation methodology has its inherent strengths and 
limitations. Some require prior chemical modification of biomolecules with non-native 
functional groups to enable site-specific immobilization. Conversely, others utilize native 
functional groups to execute covalent attachment, which offers increased biomolecular generality 
but often at the cost of random biomolecular orientation. Some techniques are limited to small-
scale gradients (100s of microns), while others have the potential to generate gradients on the 
millimeter-scale. Finally, a handful of approaches have the potential to allow the controlled 
deposition of multiple different biomolecules onto a single surface, while others are limited to 
single-component substrates. (For an extensive review of the various approaches to gradient 
generation and surface immobilization of biomolecules, see references.14a,14b) 
The approach presented herein involves the use of light as a reagent, which allows facile 
control over the spatial distribution and surface density of immobilized biomolecules.14c Glass 
substrates functionalized to present the photocrosslinking molecule benzophenone (BP) are 
utilized to directly photoimmobilize multiple classes of biomolecules onto the surface as 
governed by spatially controlled incident photon flux and solution-phase biomolecule 
concentration.14c Others have shown alternative photochemical biomolecular patterning 
strategies, often based upon either a combination of photolithographic patterning and 
bioconjugation,14d,15 or direct photochemical activation of the surface.6,16 More relevant to this 
work, BP-modified substrates were previously used in the photoimmobilization of polymers17 
and biomolecules.10b,18 However, these demonstrations were limited to generating substrates 
presenting a single biomolecule, with minimal applications in biological assays. This work 
represents the first demonstration of biomolecular photopatterning for applications in leukocyte 
biology and for the investigation of the mode of action of an anti-inflammatory therapeutic. 
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In my work with BP-modified substrates, biomolecular patterns and gradients are 
generated by immersing substrates in a solution containing the biomolecule of interest and 
exposing the substrate to light (350 – 365 nm), which results in the covalent attachment of 
biomolecules to the surface in a spatially controlled manner (Figure 1.2). When illuminated with 
UV light, BP undergoes an n→π* molecular transition, generating a triplet diradical that can 
result in the formation of a new C-C bond between the BP-modified substrate and the molecule 
of interest via a proton abstraction/radical recombination mechanism.19 If an excited BP 
molecule does not abstract a proton from a neighboring molecule, it will relax back to the ground 
state, enabling re-excitation in the presence of a different biomolecule. In this manner, I have 
demonstrated that BP-based photoimmobilization is a versatile technique for generating multi-
component gradients by sequential exposures in the presence of different biomolecule solutions, 
and that these surfaces can be used as in vitro models for biological studies.14c In choosing this 
 
Figure 1.2  Schematic representation of the generation of multi-component biomolecular 
surface patterns and gradients via sequential exposures of benzophenone-modified substrates 
in the presence of different biomolecule solutions. 
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particular gradient generation approach, I envisioned that the overall simplicity, biomolecular 
generality, and capability to generate user-specified multi-component substrates for biointerface 
studies would make this a broadly applicable platform for researchers in need of model 
substrates presenting well-defined biomolecular patterns and gradients for biological 
applications. 
Gradient substrates have a potential advantage over homogeneous substrates for 
applications in leukocyte flow assays, namely, the ability to yield high-content data by 
examining cell behavior in response to the presence of a variety of site densities on a single 
substrate. This approach is more efficient compared to the generation of numerous different 
substrates representing the different ligand densities under investigation. Additionally, the 
approach involves the covalent immobilization of biomolecules to the surface, which eliminates 
the risk of protein desorption due to disrupted non-covalent interactions. By pursuing the BP 
photopatterning approach to biomolecular substrate generation, I chose to forfeit the ability to 
control biomolecule orientation in exchange for biomolecular generality and overall simplicity.  
In addition to the traits mentioned above, mechanical stiffness is another characteristic 
that is important to consider when choosing a material that will be used to model physiological 
environments. Several studies have shown that the mechanical properties of biointerfaces can 
have a dramatic effect on cell behavior.20 In my work with BP-modified substrates, I have 
chosen to work with glass, which has a Young’s modulus of 72 GPa at 20 °C. While the 
mechanical properties of the blood vessel wall cannot be described by a single Young’s modulus, 
the three major components of the blood vessel, namely, elastin, smooth muscle and collagen, 
have Young’s moduli of 0.1-1.0 MPa, 10-100 kPa, and 0.1-1.0 GPa, respectively.21 Clearly, glass 
substrates have very different mechanical properties compared to the blood vessel. Traditionally, 
leukocyte biology researchers have utilized both glass and polystyrene for in vitro experiments 
and have verified that observations of leukocyte behavior on immobilized selectins on glass are 
representative of leukocyte behavior in vivo, which suggests that despite the differences in 
mechanical stiffness, glass substrates are suitable for in vitro leukocyte flow assays.22 However, 
to be entirely certain of the physiological implications of biological studies performed on glass 
substrates, it will be necessary to confirm all in vitro observations with follow-up studies using 
mechanically similar materials in vitro, or in mouse models of inflammation. 
6 
 
The BP gradient generation methodology that has been developed satisfies the majority 
of the criteria for the ideal substrate for leukocyte flow assays and shows promise for future 
applications in leukocyte biology and beyond, as supported by research results presented in 
Chapters 2 and 3. 
1.2 Overview of the biology underlying leukocyte recruitment and inflammation 
Physiological processes involving numerous biological molecules sustain all forms of 
life, from microscopic single-celled prokaryotes to macroscopic multicellular organisms. 
Mammals’ bodies are equipped with an immune system that is able to recruit white blood cells, 
or leukocytes, to the scene when viruses, bacteria and other potentially deadly intruders invade. 
The first step of this process, known as the inflammatory response, is the recruitment of 
leukocytes from the blood stream to the site of the injury or infection.23  
Inflammation is a two-edged sword: Although it is essential for survival, when not 
properly regulated it can wreak havoc on the very being it was intended to protect.24 Numerous 
diseases are correlated with improperly regulated inflammation, including rheumatoid arthritis, 
asthma, psoriasis, thrombotic disorders, and autoimmune disease.24 Inflammation is also 
associated with increased risk of malignancy in cancer,25 and studies suggest leukocytes found in 
the tumor microenvironment may assist in metastasis and immunosuppression.26 A 
comprehensive understanding of the molecular underpinnings of the inflammatory response is 
essential for laying the groundwork to develop more effective therapeutic interventions.  
To study inflammation, researchers have employed various biological techniques. Much 
of the in vivo biological work has centered around the generation of genetically engineered 
“knock-out” mice, which lack one of the proteins involved in the inflammatory response. Such 
studies have revealed what happens to the process of inflammation in the absence of individual 
components, and have led the research community to propose a mechanism for the leukocyte 
adhesion cascade (Figure 1.1).2 Although aspects of the proposed mechanism remain topics of 
debate, the overall consensus in the field is that inflammation happens in several sequential steps. 
First, inflammatory cytokines, secreted by dying cells and bacteria, cause endothelial cells lining 
nearby blood vessels to express elevated levels of selectins,27   which are able to recognize 
ligands on leukocytes. Selictins recruit leukocytes from the blood stream to the blood vessel 
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surface, causing them to roll along the blood vessel wall in the presence of physiological shear 
stress.28 Prolonged leukocyte-endothelium interactions29  give leukocytes the opportunity to 
interact with chemokines presented on the endothelial lining. When chemokines bind to 
leukocyte-expressed G-protein-coupled receptors (GPCRs),30  downstream signaling cascades 
cause leukocyte-expressed integrins to undergo a conformational change, which gives leukocytes 
the ability to bind to intercellular adhesion molecules (ICAMs) on the endothelial lining.31 
Leukocytes firmly adhere to the blood vessel wall,29 and finally, additional receptor-ligand 
interactions facilitate the process of diapedesis, which enables the leukocyte to pass through the 
blood vessel wall and follow chemical cues until it arrives at the site of the injury or infection.2 
 
The biological applications of the BP substrate generation methodology presented herein 
focuses on the first step of the leukocyte recruitment process: selectin-mediated leukocyte 
 
Figure 1.3  A schematic representation of the three selectins: P-, E-, and L-selectin. All three 
selectins have an N-terminal active site, composed of a lectin domain that enables calcium-
dependent carbohydrate recognition, followed by a motif known as an epithelial growth 
factor (EGF) domain and a varying number of consensus repeats, a transmembrane domain, 
and a cytoplasmic tail. 
P-selectin
E-selectin
L-selectin
transmembrane
domain
consensus repeats
EGF-like domain
active site
cytoplasmic tail
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rolling. Figure 1.3 presents a schematic representation of the three selectins: P-, E-, and L-
selectin. P-selectin and E-selectin are expressed on the inflamed endothelium and play a central 
role during the initiation of an inflammatory response: When the endothelium receives distress 
signals from underlying tissue, P-selectin is the first biomolecule deployed as it is mobilized 
from intracellular storage pools, known as Weibel-Palade bodies, to the luminal surface of the 
endothelium.32 The interaction between P-selectin and its primary leukocyte-expressed ligand, P-
selectin glycoprotein ligand-1 (PSGL-1), supports neutrophil rolling along the surface of the 
blood vessel.31a E-selectin, which binds to PSGL-1 among other ligands,33 is also presented on 
the endothelium during the inflammatory response, but its expression is largely controlled by 
translation (i.e., it is not stored intracellularly),34 and its presentation temporally lags behind that 
of P-selectin in vivo. L-selectin is expressed on most leukocytes and binds to ligands expressed 
on high endothelial venules (HEVs) of lymph nodes and an the endothelium, as well as to 
ligands on other leukocytes, in a process known as secondary tethering. P-selectin and E-selectin 
are the two major biomolecular players in inflammation because of their role in initiating the 
recruitment of leukocytes to interact with the blood vessel wall during inflammation. All three 
selectins have an N-terminal active site, composed of a lectin domain that enables calcium-
dependent carbohydrate recognition, followed by a motif known as an epithelial growth factor 
(EGF) domain and a varying number of consensus repeats, a transmembrane domain, and a 
cytoplasmic tail (Figure 1.3).35 All three selectins recognize sialylated and fucosylated 
oligosaccharides, most importantly a motif known as sialyl Lewis x (sLex), which is presented on 
several glycoproteins and glycolipids on leukocytes and some endothelial cells and is required 
for all selectins to bind to PSGL-1 and other selectin ligands. The role of selectins in the 
leukocyte adhesion cascade has been extensively reviewed.36 
While the basic framework for understanding inflammation is in place, much remains 
unknown about the molecular details underlying this complex physiological process. The 
inherent complexity and redundancy of many receptors and ligands involved in the process pose 
challenges for studying the mechanism of inflammation, and also makes it difficult to develop 
therapeutics that are able to disrupt unwanted inflammation. Among the receptor-ligand 
interactions involved in the leukocyte adhesion cascade are selectins and their ligands,37 
chemokines and their receptors,38 leukocyte integrins and their complementary intercellular 
adhesion molecules (ICAMs),29 and endogenous anti-adhesive factors.39 Given the number of 
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biomolecular players, it is reasonable to predict that multi-target therapeutics that are able to 
disrupt several receptor-ligand interactions simultaneously will be more effective than single-
target treatments for unwanted inflammation.40 Understanding the interplay between the various 
receptor-ligand interactions that occur during leukocyte recruitment will help lay the groundwork 
for the development of multi-target therapeutics, and this is the underlying motivation behind the 
biological investigations described in Chapter 3. 
1.3 Bromelain—a natural multi-target anti-inflammatory therapeutic 
Bromelain is a natural anti-inflammatory treatment that is currently used as an alternative 
or complementary treatment for treating inflammation.41 This extract from pineapple stems 
contains cysteine proteases that are known to cleave multiple cell surface molecules involved in 
the adhesion and activation leukocytes.42 Protein-based therapeutics are typically known to suffer 
from proteolytic degradation via enzymes in the digestive tract. However, bromelain taken by 
oral administration was found to be present at detectable levels in the blood plasma and exhibit 
proteolytic activity, with few adverse side effects.43 While bromelain has been demonstrated to 
have anti-inflammatory, fibrinolytic, and anti-thrombotic effects in both in vivo and in vitro 
studies,41,44 the mechanisms by which bromelain attenuates the recruitment of various leukocyte 
subsets remains poorly understood. Amongst the enzymes present in bromelain extract is stem 
bromelain, which was the focus of my studies and will be referred to as bromelain herein.  
Bromelain (EC 3.4.22.32) has a molecular mass of 23,800 Da and is commercially 
available as a complex mixture with other components that are not completely characterized but 
include phosphatases, glucosidases, peroxidases, cellulases, glycoproteins and carbohydrates.41 
Bromelain has a broad substrate spectrum and is able to cleave substrates ranging from low 
molecular weight peptides to high molecular weight substrates such as fibrin, albumin and 
casein. Bromelain’s substrate specificity is not fully characterized, but it has been found to 
cleave most efficiently at Arg-Arg sites of synthetic substrates45 and to preferentially cleave 
glycyl, alanyl and leucyl bonds.41 However, it is difficult to predict potential protein cleavage 
sites since natural proteins have been found to exhibit broader susceptibility to bromelain 
cleavage than that of synthetic substrates.42  
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In an attempt to understand the molecular basis of bromelain’s anti-inflammatory 
properities, other research labs have investigated the effects of bromelain treatment on neutrophil 
migration in response to chemokines, which is the step in the leukocyte adhesion cascade 
immediately following leukocyte transmigration through the blood vessel wall.42,46 In the first of 
these studies, performed under the direction of Laura P. Hale, neutrophils were isolated from 
whole blood, treated with bromelain, and analyzed for the expression of numerous ligands and 
receptors using flow cytometry.42 Follow up studies were performed in the same lab to 
investigate how bromelain treatment affected neutrophils migration in response to IL-8 and 
fMLP, two known inducers of cell migration, both in vitro and in mouse models of 
inflammation.42  
While others have investigated the effects of bromelain treatment on neutrophil 
migration, there are no previous studies on the effects of bromelain on selectin-mediated 
leukocyte rolling, the first step of the leukocyte adhesion cascade. In the work described in 
Chapter 4, I set out to fill this literature gap, motivated by the desire to shed additional light on 
potential mechanisms by which bromelain exerts its therapeutic benefits in inflammatory 
conditions. Such information will be useful to researchers and doctors interested in 
understanding bromelain’s mode of action and developing more effective treatments for 
dysregulated inflammation. 
1.4 In vivo and in vitro approaches to studying leukocyte recruitment 
Mechanistic biological studies are extremely challenging to carry out in vivo due to the 
complexity of the physiological environment in which inflammation naturally occurs. In such a 
highly variable and difficult-to-control environment, it is essentially impossible to parse apart all 
the variables and determine which parameter (e.g., protein expression level, rate of blood flow) 
causes which behavior (e.g., cell rolling, cell adhesion). To further complicate matters, many of 
the receptor-ligand interactions involved in leukocyte recruitment are redundant and have 
functionally overlapping roles. This redundancy serves to confound studies involving knock-out 
mice, since engineered mice may find ways to adapt and compensate for the missing protein.22a 
To avoid the added complications that come with studies involving gene targeted disruption of 
specific ligands in mice, others have looked to commercially available function-blocking 
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antibodies to functionally remove specific proteins and observe the outcome. However, this 
approach comes with its own potential complications such as incomplete blocking or non-
specific antibody binding.22a 
The majority of in vivo mouse studies on inflammation are aimed at addressing questions 
regarding the role of a particular protein in leukocyte recruitment. However, questions regarding 
the interplay between different biomolecules involved in leukocyte recruitment are more 
challenging, if not impossible, to address with standard in vivo experiments because of the 
complexity inherent to living systems. Researchers have consequently looked to in vitro studies 
for answers to these questions.  
Successful in vitro experiments require model systems47 with properties that can be tuned 
by the experimenter to represent some aspect of a biological system. Two common approaches to 
generating model substrates for studying leukocyte recruitment include immobilizing a protein 
involved in inflammation on a surface, or generating monolayers of endothelial cells for use as 
blood vessel models. By having the ability to alter one or two parameters (e.g., protein site 
density, flow rate) in a controlled and quantifiable manner, researchers can determine the 
relationship between the variable parameter and the subsequent observed leukocyte behavior. 
The ultimate goal of an in vitro model substrate for inflammation is not necessarily to mimic the 
in vivo biological environment, but to serve as a well-defined and easily controlled substrate that 
yields quantitative information about cause-and-effect relationships between substrate 
composition and cell behavior.  
Leukocyte flow assays have indeed provided additional pieces to the complex puzzle of 
inflammation and have enhanced the current understanding of the mechanism underlying the 
process of leukocyte recruitment. For example, researchers led by Daniel A. Hammer have 
performed numerous biophysical studies to understand the molecular basis of selectin-ligand 
binding by using receptor-coated substrates and studying the interactions of ligand-coated 
microspheres with selectin-coated surfaces under various conditions.48 Another team of 
researchers led by Rodger P. McEver used substrates presenting immobilized PSGL-1 to 
demonstrate the first in vitro observation of “catch bond” behavior, a phenomenon in which the 
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affinity between a receptor-ligand pair increases as shear stress increases up to a point of 
optimum shear stress, beyond which interactions convert to “slip bond” behavior.49  
In addition to these examples, numerous other studies have shown that selectin-mediated 
rolling under conditions of physiological shear stress can be studied in an in vitro flow assay 
format, yielding new insights into the biophysical phenomena underlying the first step of 
leukocyte recruitment.13a,50 However, the substrates employed as model substrates are typically 
made by non-specifically adsorbing proteins onto a surface,48d,51 yielding substrates that are 
susceptible to changes over time.1,14b In addition, to probe the effect of surface density on cell 
behavior using this approach would require that numerous substrates be generated and that 
multiple separate experiments be performed in sequence. In other cases, researchers have used 
cytokine-stimulated endothelial cell monolayers52 that express multiple ligands in a 
physiologically relevant manner. While there are certain advantages to using cell monolayers as 
a blood vessel model compared to surface-immobilized protein substrates, the primary downside 
of the approach is it offers little control over the site density of the ligands presented.  
While typical model substrates present one biomolecule at a uniform site density, a 
handful of previous studies report the use of substrates with two biomolecules deposited on the 
surface at varying levels.51,53 However, using non-specific adsorption to generate two-component 
substrates for experiments requires that numerous substrates be generated to represent all 
possible iterations of protein levels for each biological assay. This time- and resource-intensive 
approach is non-ideal for yielding information in a timely and efficient manner.  
The ideal model substrate for in vitro leukocyte flow assays would therefore allow the 
researcher to: 
1. Covalently attach biomolecules to the surface 
2. Immobilize biomolecules in user-defined patterns and gradients 
3. Control biomolecule orientation and/or quantify ligand site density 
4. Immobilize multiple biomolecules on a single substrate 
A method that meets these criteria would help remedy the short-comings of traditional 
approaches to the generation of model substrates for applications in leukocyte biology and 
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beyond.  Such a technique would be of enormous value to the field of leukocyte biology in that it 
would enable new insights into the combined effect of biomolecular site density and other 
parameters on cell behavior in an efficient and resourceful manner. The BP photopatterning 
approach described herein satisfies the above criteria for model substrate generation, and thus 
holds promise for revealing new insights about the leukocyte adhesion cascade. 
Beyond applications in leukocyte biology, a methodology for the generation of 
biomolecular surface gradients is of fundamental interest for in vitro assays enabling the 
investigation of cell migration and polarization in response to immobilized protein 
concentration,4a,54 and for multi-parameter studies in cell biology that systematically address the 
combined effects of multiple stimuli, such as the density of multiple biomolecules, topography, 
and shear stress on cell behavior.55 The focus of my doctoral research, and the focus of this 
manuscript, is on applications of the developed BP-mediated surface-immobilized gradient 
generation methodology in leukocyte biology. 
1.5 Overview of work presented herein 
This chapter presented an overview of strategies for biomolecular pattern and gradient 
generation, leukocyte recruitment and inflammation, bromelain, and approaches to studying 
leukocyte recruitment.  
Chapter 2 describes the development of a molecularly general photochemical method that 
utilizes BP-functionalized surfaces to generate biomolecular patterns and gradients. The 
substrates generated present covalently immobilized biomolecules at defined and varied site 
densities. Data is presented that demonstrates the quantitative determination of biomolecule 
deposition, substrate versatility, retention of protein functionality, and ability to deposit multiple 
biomolecules onto the same surface, as well as preliminary demonstrations of cell adhesion and 
leukocyte flow assays on biomolecular patterns and gradients. These initial studies demonstrate 
that the BP approach to biomolecular substrate generation is an attractive methodology for a 
wide range of biomaterials and biointerface research applications that rely upon defined 
biomolecular interfaces. 
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Chapter 3 presents the generation of single- and multi-component substrates for multi-
parameter leukocyte flow assays for the investigation of selectin-mediated rolling of two 
immortalized leukocyte model cell lines, HL-60 promyelocytes and Jurkat T lymphocytes. The 
results of these proof-of-principle investigations reveal the combined effect of immobilized 
protein site density and applied wall shear stress on cell rolling behavior, and shows that the 
described gradient generation approach yields well-defined substrates with the ability to present 
immobilized proteins over a large range of site densities. Data is presented that demonstrates the 
first application of two-component biomolecular substrates to probe the transition from rolling to 
adhesion of leukocytes under conditions of physiological shear stress. The findings show that BP 
biointerface substrates can be applied to the investigation of cell-substrate interactions in the 
context of multi-parameter leukocyte flow studies. 
Chapter 4 presents the results of in vitro studies that help shed light on the molecular 
mechanism underlying the anti-inflammatory effects of bromelain, a multi-target anti-
inflammatory therapeutic. A natural proteinase preparation isolated from pineapple stems, 
bromelain has been demonstrated to proteolytically alter multiple cell surface molecules 
involved in the adhesion and activation of certain leukocyte subsets42 and is currently used as an 
alternative or complementary medication for treating inflammation.41 Other research labs have 
investigated the effects of bromelain treatment on neutrophil migration in response to 
chemokines, but the investigation outlined in Chapter 4 represents the first to reveal that 
bromelain cleaves a ligand involved in selectin-mediated leukocyte rolling, the first step of the 
process of leukocyte recruitment. The findings from these investigations will be useful in the 
development of more effective treatments for dysregulated inflammation and the diseases 
associated with it. 
Chapter 5 presents a summary of all this work and a detailed plan for future 
developments and applications of the BP gradient methodology in leukocyte biology.  
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Chapter 2 
 
Direct Biophotolithographic Method for Generating Substrates with 
Multiple Overlapping Biomolecular Patterns and Gradients 
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2.1 Introduction 
Cellular adhesive environments are composed of many distinct biomolecules whose 
density and spatial distribution determine the response of cells. To better understand the nature 
of these complex interfacial recognition events and subsequent processes, scientists have utilized 
expertise in molecular synthesis, design, and control to influence the behavior of cells,1 resulting 
in well-defined surfaces presenting biologically relevant ligands at distinct spatial 
locations.2 Particularly challenging to fabricate are surface-immobilized gradients in which the 
density of a specific biomolecule is spatially varied in a continuous (rather than digital) manner. 
However, in vivo, numerous biomolecules are involved in defining adhesive environments. Thus, 
a further challenge exists in generating multi-component, overlapping surface gradients wherein 
the surface density of multiple biomolecules is spatially controlled. 
On a broader level, there is a growing interest in surface chemical approaches for the 
generation of substrates presenting patterned biomolecules for applications in biointerface 
science,3 microarray technology,4 biosensors,5 microfluidics and point-of-care applications,6 and 
nanotechnology.7 Biomolecular patterning tools have been rapidly developing due to a growing 
interest in exercising spatio-temporal control over protein patterns,1 characterizing immobilized 
protein site density for quantitative biointerface studies,8 and generating substrates presenting 
multiple ligands to model complex physiological environments.9 The most advantageous 
patterning approaches are those that are simple, molecularly general, quantifiable, and easily 
extendable to create substrates with higher levels of biomolecular complexity. 
Several approaches have been developed to generate substrates presenting immobilized 
biomolecules. Surface-immobilized biomolecular gradients can be formed by first generating 
chemical gradients on surfaces, via chemical or photochemical modification of surface functional 
groups10 or the manipulation of self-assembled monolayers9e,11 followed by the conjugation of 
biomolecules via various chemical functionalities. Alternatively, biomolecular gradients can be 
created in solution by controlled mixing in microfluidic networks followed by direct transfer to a 
uniform surface.3b,12 Surface gradients generated via these approaches have proven to be 
exceedingly valuable in investigating biological processes such as cell polarity,12a migration and 
metastasis,3b,11b,13 wound healing,14 and neuronal guidance.12b,12c However, many of these 
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enabling approaches require complicated microfluidic designs, have limits on the number of 
components incorporated, or require specific and often non-native chemical functionalities, 
which can limit their general applicability to different classes of biomolecules (peptides, 
proteins, carbohydrates, etc.). Other groups have developed biomolecular patterning strategies 
based upon either a combination of photolithographic patterning and bioconjugation15 or direct 
photochemical activation of the surface.10,16 More relevant to this work, benzophenone-modified 
substrates were previously used in the photoimmobilization of polymers17 and biomolecules.5b,18  
In this report, a direct, biomolecularly general method for creating overlapping, 
multicomponent patterns and surface gradients is described. The approach, outlined in Scheme 
2.1, involves the spatially selective photochemical activation of benzophenone (BP) monolayers 
in the presence of a solution-phase biomolecule. Upon illumination with 365 nm light, BP 
undergoes an n → π* transition to form a transient diradical that can covalently attach proximal 
biomolecules to the surface via insertion into a C−H bond.19 Excited BP molecules that fail to 
undergo C−H insertion relax back to the ground state whereby they can be re-excited in the 
presence of a different biomolecule solution, allowing for the creation of overlapping patterns 
and gradients. Because of the general reactivity of BP towards ubiquitous C−H bonds, this 
method represents a general approach for direct surface bioconjugation. Other groups have taken 
a similar approach to using BP to generate biomolecular patterns and gradients, but instead of 
attaching unmodified biomolecules to BP-modified substrates, they attach BP to the biomolecule 
and use light to attach the BP-labeled biomolecule to the surface.20 However, this approach is 
susceptible to biomolecular cross-linking in solution and multilayer formation because the 
reaction is not confined to the surface.  
In my work with BP-modified substrates, biomolecular patterns are generated by 
immersing substrates in a solution containing the biomolecule of interest and exposing the 
substrate to light through a photomask (350 – 365 nm), which results in the covalent attachment 
of biomolecules to the surface in a spatially controlled manner (Scheme 2.1). I describe the first 
application of BP photochemistry to generate surface-immobilized biomolecular patterns and 
gradients with the ability to attach both proteins and carbohydrates.  
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Scheme 2.1  A schematic diagram showing the preparation of BP-modified substrates and 
subsequent biomolecule photoimmobilization. Glass microscope slides are cleaned, silanized 
and functionalized with BP. A biomolecule is introduced to the substrate followed by 
exposure to UV light (~365 nm), resulting in the formation of new C-C bonds between the 
surface and the biomolecules. The resulting biomolecular patterns are visualized with a 
fluorescently labeled binding partner. 
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The BP photopatterning methodology was applied to create substrates that present one or 
two discrete biomolecules in patterns and gradients, and demonstrate, via a radioimmunoassay, 
that this methodology affords quantitative control over the density of biomolecule deposition 
immobilized onto the underlying substrate. Subsequent ligand-binding assays and cell adhesion 
experiments showed that specific ligand recognition occurs and that cells adhere selectively to 
immobilized capture ligands, indicating that the photopatterned molecules are not rendered 
biologically inactive. These results demonstrate that BP-based photoimmobilization is a versatile 
technique for generating multi-component patterns and gradients by sequential exposures in the 
presence of different biomolecule solutions, and that these surfaces can be applied as in vitro 
models for biological studies.21 Together with the molecular generality afforded by the C-H bond 
insertion mechanism, the advantages of this direct photochemical attachment methodology, such 
as quantitative deposition, retention of protein functionality, and the ability to deposit multiple 
biomolecules onto the same surface, make this approach attractive for a wide range of 
biomaterials research applications that rely upon defined biomolecular interfaces and the creation 
of substrates that serve as models of complex physiological microenvironments 
2.2 Results and Discussion 
I have developed a straight-forward and versatile technique for generating photopatterned 
biomolecular substrates that are suitable for probing receptor-ligand interactions and for 
biointerface studies. BP-modified substrates are assembled into a flow chamber and exposed to 
UV light in the presence of a biomolecular solution to generate patterns or gradients (Scheme 
2.1).  The resulting patterns are visualized by recognition with a fluorescently labeled antibody, a 
native ligand, or by selective cell adhesion.  
2.2.1 Chemical characterization of BP-modified substrates  
BP-modified substrates were prepared and characterized after each step by water contact 
angles (Table 2.1). Freshly cleaned substrates were extremely hydrophilic, giving an 
unmeasurable contact angle as reported in the literature.22  Following vapor phase silanization, 
the water contact angle increased to 44.8 (±1.9)°, indicating an increase in hydrophobicity due to 
the addition of the monolayer onto the glass substrate. These values are within the range of 
values reported in the literature for aldehyde-functionalized surfaces.9f,23  Subsequent attachment 
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of BP further increased the hydrophobicity of the surface, giving a water contact angle of 53.4 
(±1.1)°. After protein conjugation to the BP-modified surface, a ~20° decrease in contact angle is 
observed, which is consistent with literature reports.15c  Given the significant changes in the 
relative hydrophobicity measured during each step of this procedure, water contact angle 
measurements were routinely used to verify the success of each chemical modification step.  
 
In order to confirm that the derivatization procedure did not lead to significant changes in 
substrate topography, the surface roughness following each chemical and biochemical 
functionalization step was monitored using atomic force microscopy (Table 2.1). Through the 
entire surface functionalization procedure and subsequent photoimmobilization of a 
representative protein, the root mean squared (rms) roughness of the substrates increased 
slightly, from 352 pm for the clean glass surface to 775 pm for the protein-modified substrate, 
revealing no dramatic changes in surface topography.24 
2.2.2 Generation of substrates presenting biomolecular patterns and gradients 
I first demonstrated the ability to create single-component protein patterns with 
biotinylated lectin Concanavalin A (ConA-biotin) on BP-modified glass substrates. After 
 
Table 2.1  Surface characterization of BP-modified substrates. Surfaces were characterized 
using contact angle goniometry and AFM to determine changes in hydrophobicity and surface 
roughness. Contact angle data represent the average of n=9 substrates (± standard deviation) 
from two batches of slides made on the same day.  AFM analysis was performed on BP-
modified silicon after each reaction and the RMS roughness was determined.  
 
Glass Aldehyde silane BP functionalization Post-Protein Conjugation
Contact Angle 
(H2O)
0° 44.8 ± 1.9° 53.4 ± 1.1° 30.2 ± 2.1°
RMS Roughness 
(AFM)
352 pm 915 pm 833 pm 775 pm
Chemical 
Structure
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introducing the solution-phase protein to a BP-modified substrate, the substrate was illuminated 
through a 500-μm square photomask pattern followed by visualization with a fluorescently 
labeled binding partner, as shown in Figure 2.1a. I extended the protocol to generate two-
component biomolecular patterns by sequentially exposing the same substrate in the presence of 
two different biomolecules. More specifically, the BP surface was illuminated through the 
photomask in the presence of mannan, followed by rotation of the mask 45° and exposure in 
the presence of P-selectin. The resulting overlapping patterns were visualized with two spectrally 
distinct fluorescently labeled binding partners (Figure 2.1b). To my knowledge, the resulting 
two-component substrate is the first example of overlapping patterns of carbohydrates and 
proteins on the same substrate. 
 
Upon the basis of the digital patterning results shown in Figure 2.1, it was reasonable to 
believe that gradients of biomolecules on the surface could be generated by continuously varying 
 
Figure 2.1  Demonstration of direct photoimmobilization of proteins and carbohydrates on 
BP-modified glass substrates: (a) biotinylated ConA and (b) overlapping patterns of 
glycoprotein P-selectin (red) and polysaccharide mannan (green). Dashed lines indicate areas 
in the fluorescence line scans. F.I. stands for fluorescence intensity. Scale bars: 500 μm. 
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the spatial exposure across the surface during illumination. In addition to the spatial exposure to 
UV light, the relative amount of surface attachment can also be controlled by adjusting the 
concentration of solution-phase biomolecule. Figure 2.2a demonstrates both of these levels of 
control in the fabrication of one-component continuous surface gradients of ConA-biotin by 
positioning a programmable shutter in between the light source and the substrate. Illumination 
and linear movement of the shutter were initiated simultaneously so that a gradient in light 
exposure was created across the substrate. Gradient profiles at three different ConA-biotin 
concentrations show the relationship between solution-phase biomolecule concentration and the 
slope of the resulting gradient.  
 
Similarly to the two-component patterning demonstration, parallel overlapping gradients 
of P-selectin (red) and mannan (green) were fabricated by sequential exposures with 180° shutter 
 
Figure 2.2  Demonstration of control over gradient profile and biomolecular generality of the 
photochemical approach: (a) biotinylated ConA gradient slope can be controlled by varying 
the biomolecular concentration during photoimmobilization and (b) a single substrate 
displaying two overlapping gradients of P-selectin (red) and mannan (green). F.I. stands for 
fluorescence intensity. Scale bar: 500 μm. 
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reorientation, as shown in Figure 2.2b. I was also able to generate two-component perpendicular 
gradients by rotating the shutter by 90°, as shown for mannan and P-selectin in Figure 2.3. 
Notably, the photochemical approach allows the immobilized biomolecule concentration to be 
varied along the direction of flow. A diagonal line drawn from bottom left to top right across 
Figure 2.3a gives an identical profile to that of Figure 2.2b, whereas the diagonal from top left to 
bottom right shows both components varied together from high to low concentration. These 
results suggest that the simplicity and versatility provided by the BP-patterning methodology will 
allow the facile construction of complex, overlapping gradient substrates that will find utility in 
future studies of cell−substrate interactions. 
 
 
Figure 2.3  Two-component biomolecular gradients on BP-modified substrates with 
perpendicular gradient profiles yield substrates that present different ratios of two 
components in various regions. (a) Fluorescence image and line scans of overlapping 
gradients of mannan (green) and P-selectin (red), parallel and perpendicular to the direction of 
solution flow, respectively. Dashed lines indicate areas in fluorescence line scans. (b) 
Illustration of how perpendicular gradients substrates present numerous “microenvironments” 
with different relative ratios of the two components on a single substrate. 
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2.2.3 Quantitative determination of protein site density 
Determining the site density of ligands as a function of UV exposure time allows 
substrates to be tailored to present specific concentrations of ligands for subsequent applications. 
Substrates were patterned to present uniform ConA-biotin over a range of site densities. The 
resulting F.I. data were plotted as a function of exposure time (Figure 2.4). Protein site density 
was quantified by incubating substrates with a saturating concentration of [125I]-labeled 
streptavidin. Calibration plots were made using known concentrations of [125I]-labeled 
streptavidin, and the resulting radioactivity (CPM) for each concentration of [125I]-labeled 
streptavidin was plotted as CPM vs. number of molecules (data not shown). Using the calibration 
 
Figure 2.4  Protein loading is positively correlated with UV exposure time. Biotinylated 
ConA (5 µg/mL) was uniformly photopatterned onto BP-modified substrates for 5, 15, 30, 60, 
or 120 sec. The signal from subsequent (a) fluorescence analysis and (b) radioimmunoassays 
shows that signal increases with increasing UV exposure time (~365 nm, 17 mW/cm2). 
Control substrates were employed to account for nonspecific binding of antibodies. Data 
points represent the average of n=3-4 (± 95% C.I.).  
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plot, and knowing the analysis area, the site density (molecules/µm2) was determined for each 
exposure time. Since fluorescence measurements are considerably more convenient to perform 
on substrates compared to radioiummunoassays, site density was plotted against the F.I. for each 
time point to establish a correlation to convert from fluorescence to loading density (Figure 2.5). 
Increasing the exposure time results in higher densities of immobilized ligands on the substrate, 
with a maximum loading value, under the patterning conditions used, observed at approximately 
200 molecules/µm2.  
 
Figure 2.5  Results from fluorescence-radioactivity correlation studies. Data from the 
biotinylated ConA radioimmunoassay (Figure 2.4a,b) were converted from units of CPM to 
site density using the linear regression from a standard curve generated from known amounts 
of [125I]-labeled Streptavidin (Figure 2.4c). Plotting fluorescence intensity (F.I.) as a function 
of ConA-biotin site density allows data from future fluorescence analyses to be converted to 
protein site density.  
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2.2.4 New light source for photopatterning applications 
 One of the limitations of the initial photopatterning setup came from the diffuse LED 
light source. Due to light scatter, I observed that patterns had increasingly higher “background” 
levels (immobilized protein in areas that were not directly exposed to light) with longer 
 
Figure 2.6  The optical configuration used to generated an expanded, homogenized beam of 
collimated light (λ= 351.1-363.8 nm). (a) The unmodified Coherent Ar ion laser beam has a 
Gaussian profile. As the beam is expanded and passed through a set of refractive optics, the 
Gaussian profile is converted to a flat-top, while retaining collimation. Optics I and II make 
up the Keplerian telescope that expands the beam four-fold to have the appropriate diameter 
to enter the πShaper. Optics III and IV make up the Keplerian telescope that expand the beam 
an additional three-fold, resulting in the optimized field of light for photopatterning 
applications. Lens I, plano-convex, f = 25.4 mm; Lens II, plano-convex, f = 100 mm; Lens 
III, plano-convex, f = 50 mm; Lens IV, plano-convex, f = 150 mm.  (b) A beam profiling 
camera was used to acquire images of the beam before and after passing through the πShaper.  
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illumination times, limiting the signal-to-noise (S/N) ratio that could be obtained (data not 
shown). For the same reason, the maximum difference in F.I. observed across a gradient was 
consistently a factor of 2 to 3. This would severely limit future investigations of cell-substrate 
interactions over a wide range of immobilized ligand densities, since gradients presenting ligands 
over a broad range of surface densities would be unattainable. 
 To solve this problem, I obtained an Ar ion laser (351.1-363.8 nm), which has a highly 
collimated output. Collimated light is composed of parallel light rays that disperse slowly with 
distance. I envisioned this would decrease unwanted light scatter during photopatterning and 
minimize background protein attachment, enabling the generation of gradients presenting a 
broader range of site densities. An instrument known as a πShaper (MT Berlin) was used in 
conjunction with several optical components to convert the Gaussian profile to a homogeneous 
or “flat-top” output and expand the beam for large-area photopatterning (Figure 2.6). This new 
laser setup enabled us to generate patterns with a S/N ratio of ~15, compared to ~2 with the UV 
 
Figure 2.7  Switching light sources from the UV LED to the laser+πShaper enabled an 
increase in S/N ratio from 2 to ~15. Presumably, the increase in S/N is the result of switching 
from a diffuse light source, which leads to high background immobilization due to light 
scatter (left), to a collimated light source that minimizes background immobilization (right). 
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LED light source (Figure 2.7). 
2.2.5 Demonstration of immobilized protein function: ligand recognition and cell patterning 
Common applications of substrates presenting immobilized biomolecules include 
recognition of native ligands and cell adhesion studies. It is therefore important to verify that the 
photoimmobilization process, which involves exposure to UV light (λ = 351.1-363.8 nm), does 
not physically damage biomolecules such that they can no longer be recognized by appropriate 
receptors on the surface of cells. To demonstrate the ability of photopatterned proteins to retain 
their specific ligand-binding properties, I generated substrates presenting photopatterned P-
selectin in an array of circles and squares (Figure 2.8).  P-selectin is a glycoprotein involved in 
leukocyte tethering on the endothelial lining of blood vessels and HL-60 cells are known to 
express PSGL-1, a receptor for P-selectin.8a The resulting images suggest that P-selectin is able 
to bind specifically to both soluble PSGL-1 (Figure 2.8a) and cell surface-bound PSGL-1 
expressed on HL-60 promyelocytic cells (Figure 2.8b). HL-60 cells, which were fluorescently 
labeled for visualization purposes, specifically adhere to the square patterns of P-selectin and not 
 
Figure 2.8  Native ligand recognition demonstrated with photopatterned glycoprotein P-
selectin.  (A) P-selectin was immobilized onto BP-modified substrates in 800-µm circles.  
Fluorescence images were obtained by incubating substrates with PSGL-1.  (B) HL-60 
promyelocytes, which express PSGL-1 on their surface, selectively adhere to 500-µm squares 
of photoimmobilized P-selectin on BP-modified substrates, as visualized by fluorescent cell 
labeling and microscopy.  Scale bars: 500 µm.  
(a)
PSGL-1
P-selectin
(b) PSGL-1 on 
cell surface
P-selectin
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to the surrounding background, thereby demonstrating the integrity of the photoimmobilized 
biomolecule and suggesting a general utility of the BP attachment scheme to creating cell-
compatible biointerfaces. 
The interaction of HL-60 cells with photochemically generated gradients of P-selectin 
was also investigated. As shown in Figure 2.9a, the number of immobilized cells correlates with 
the amount of immobilized P-selectin, as the degree of HL-60 attachment decreases from left to 
right down a P-selectin gradient. Control experiments showing no cell adhesion were carried out 
 
Figure 2.9  HL-60 cells adhere to and roll on immobilized P-selectin gradient substrates. (a) 
Optical micrograph of HL-60 cells seeded onto a 3-mm surface gradient of P-selectin overlaid 
with the corresponding line scan showing the gradient in the number of immobilized cells. (b) 
Plot of HL-60 cell rolling velocity versus position on a 6-mm P-selectin gradient. The wall 
shear stress was 0.24 dyn/cm2. Error bars represent the 95% confidence intervals determined 
for n = 44, 44, 46, 40, 45, 39, and 49 cells at positions 0−6 mm, respectively. 
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on nonspecific protein surfaces as well as on surfaces presenting no protein ligands (data not 
shown). As a further demonstration of the utility of photochemically generated biomolecular 
gradients as cell adhesive models, I investigated the rolling behavior of HL-60 cells as they were 
flowed perpendicularly over a P-selectin surface gradient (Figure 2.9b). The observed range of 
rolling velocities and the correlation between adhesion and the amount of immobilized P-selectin 
is consistent with previous reports.25 HL-60 cells were not observed to adhere to or roll on 
surfaces of photoimmobilized nonspecific proteins or plain BP-modified substrates. This proof-
of-principle demonstration of leukocyte rolling on BP-modified substrates presenting 
photoimmobilized P-selectin demonstrate the potential of the BP photopatterning approach for 
fundamental applications in leukocyte biology. 
2.3 Conclusion 
 In this work, I generated BP-modified substrates and characterized each surface 
modification step. I applied the methodology to create multi-component patterns of both proteins 
and carbohydrates. Furthermore, I employed a modified radioimmunoassay technique to 
establish the quantitative nature of biomolecular immobilization, which can be optimized by 
adjusting the UV exposure time. The data presented herein show that BP-modified substrates can 
be used to make spatially confined protein patterns and show that photopatterned biomolecules 
retain their ability to recognize their native ligands and to be recognized by native cellular 
receptors. An alternative to conventional gradient generation methods, this simple surface-
modification approach requires only a UV light source and translation stage, provides 
molecularly general direct covalent attachment, and allows the patterning of multiple 
biomolecules into patterns and gradients. I also demonstrated the potential of BP-modified 
substrates to be applied to studying cell-substrate interactions, by performing a leukocyte flow 
assay to demonstrate leukocyte rolling on immobilized P-selectin gradients. 
2.4 Materials and Methods 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and used as received, 
unless otherwise noted.  
2.4.1 Preparation of BP-modified substrates 
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Glass microscope slides (Fisher Scientific) were cleaned with Piranha solution (4:1 (v:v) 
concentrated H2SO4 : 30% H2O2 ).26 Substrates were rinsed extensively with water (ELGA 
LabWater Reservoir, Veolia Water Systems) and absolute ethanol (Decon Laboratories), and 
dried under a stream of nitrogen. Slides were baked in an oven at 120 ºC for 1 hr, cooled to room 
temperature, and positioned upright along the wall of a vacuum dessicator, with 100 µL of 3-
(triethoxysilyl)butyl aldehyde (Gelest) placed in the center of the chamber. Vacuum was applied 
to the sealed chamber and vacuum deposition of silane onto the glass slides was allowed to occur 
for 2.5 hr. Slides were then cured at 120 ºC for 1 hr, soaked in absolute ethanol for 30 min, 
rinsed with absolute ethanol, and dried under a stream of nitrogen. Successful silanization was 
determined via measurement of water contact angles (Ramȇ-Hart Goniometer).  
Slides were then incubated in the dark for 4 hr at rt in the presence of 20 mM 4-benzoyl 
benzylamine hydrochloride (Matrix Scientific) and 200 mM NaCNBH3 in a solution of 4:1 
DMF:MeOH, followed by immersion in aldehyde-blocking buffer (0.1 M Tris, 200 mM 
ethanolamine, pH 7.0) for 1 hr at room temperature. Slides were rinsed thoroughly with water, 
DMF, methanol, and ethanol, dried under a stream of nitrogen. The resulting BP-modified 
substrates were stored in a dessicator in the dark until further use.  
2.4.2 AFM analysis of surface roughness 
AFM measurements were performed using an MFP-3D microscope (Asylum Research). 
Substrates were prepared as described above, except silicon wafers were used instead of glass 
microscope slides. Changes in the surface roughness of the substrates after each chemical 
treatment were monitored by obtaining 1 × 1 µm topographic images in AC mode using a silicon 
probe with <10 nm tip radius and a cantilever nominal force constant of 40 N/m 
(BudgetSensors). Roughness values were calculated from the root mean square of the height 
amplitudes after the images were corrected for sample tilt using the MFP-3D imaging analysis 
and statistical software.   
2.4.3 Generation of biomolecular patterns and gradients on BP-modified substrates: UV LED 
The following biomolecules were used in photoimmobilization studies: biotinylated 
Concanavalin A (ConA-biotin), purchased from Vector Laboratories; mannan isolated from 
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Saccharomyces cerevisiae; recombinant human P-selectin (CHO cell-derived), purchased from 
R&D Systems; and fibronectin (FN), purchased from Invitrogen.  Protein stock solutions were 
prepared by resuspending lyophilized protein in the recommended buffer solutions (1x PBS for 
proteins) to a concentration of 1 mg/mL. Aliquots were stored frozen at -20 ºC until further 
dilutions in the respective buffers were freshly prepared to yield solutions of 5 µg/ml for 
photopatterning applications.  A solution of mannan was prepared by diluting lyophilized 
powder to a final concentration of 20 mg/ml in purified water for photopatterning applications.  
A rectangular parallel-plate flow chamber (GlycoTech) was assembled with a BP-
modified glass substrate separated by a silicone gasket of 127 μm thickness, 6 cm length, and 1 
cm width. Vacuum was applied to hold together the substrate-chamber assembly. Appropriate 
connectors and tubing for the solution inlet and outlet were assembled, and a syringe pump 
(Harvard Apparatus) was utilized to pull biomolecule solutions through the chamber. Prior to 
irradiation with UV light, the biomolecule solution was flowed through the chamber at a rate of 3 
mL/min.  During UV irradiation, biomolecular solution flow was stopped, or biomolecule 
solutions were flowed at a rate of 10 μL/min. Illumination for data shown in all figures was 
performed at 3 mW/cm2 through the back of the substrate with a CF2000 UV LED source (365 
nm, Clearstone Technologies), with the exception of Figures 2.7b and 2.8a, in which case 
illumination was performed with the laser+πShaper setup. For gradient generation, an opaque 
shutter connected to a computer-controlled translation stage (ThorLabs Opto dc driver) was 
programmed to move at a velocity of 0.1 mm/s for protein immobilization and 0.02 mm/s for 
carbohydrate immobilization, with total light exposure determined by the size of the desired 
gradient. Following illumination, substrates were immersed in an appropriate rinse solution and 
sonicated on ice. The following rinse solutions were utilized: for ConA-biotin, 0.5% Tween 20 in 
HEPES buffer; for mannan, 0.5 mg/mL sodium dodecyl sulfate in Dulbecco’s PBS buffer; and 
for P-selectin, 0.5% Tween 20 and 1% BSA in Dulbecco’s PBS buffer with Ca2+and Mg2+. 
2.4.4 Setting up new light source: Ar ion laser with refractive beam optics  
 The optical configuration used to generated an expanded, homogenized beam of 
collimated light is shown in Figure 2.6. I obtained an Argon ion laser (Coherent Innova 90-4, 
Laser Innovations), which has a UV output (λ = 351.1-363.8 nm) and a Gaussian profile with a 
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diameter of approximately 1.5 mm (at 1/e2), as determined with a laser beam-profiling camera 
(Ophir-Spiricon). I placed mirrors in line with the beam to direct it through the πShaper, which 
consists of a set of refractive beam optics. As the beam passes through the πShaper, the Gaussian 
profile is converted to a flat-top. Lenses I and II (plano-convex, f = 25.4 mm; and plano-convex, 
f = 100 mm, respectively, positioned approximately 125 mm apart) make up the Keplerian 
telescope that expands the beam four-fold, from a diameter of 1.5 mm to 6 mm, such that it has 
the appropriate diameter to enter the πShaper. Lenses III and IV (plano-convex, f = 50 mm; and 
plano-convex, f = 150 mm, respectively, positioned approximately 200 mm  apart) make up the 
Keplerian telescope that expand the beam an additional three-fold, from a diameter of 6 mm to 
18 mm, resulting in the optimized field of light for photopatterning applications. The πShaper 
was mounted on an x,y,z-translation stage which enabled it to be positioned precisely in line with 
the beam. All other optics were mounted with stationary lens mounts that were positioned 
directly in line with the beam. At each step of the setup, and prior to each photopatterning 
application, the profile of the beam was measured with the laser camera and modifications to the 
positions of optics and the πShaper were made until a flat-top output of the desired intensity was 
achieved. 
2.4.5 Generation of biomolecular patterns and gradients: laser + πShaper 
For data presented in Figures 2.7b and 2.8a, the BP-modified substrate in the assembled 
device was positioned face-down (allowing for illumination through the back of the glass 
substrate) beneath the UV output of the laser+πShaper setup. The laser light was homogenized 
using refractive beam-shaping optics (π-Shaper), as described above. The laser power was 
adjusted to give a final illumination intensity of 14 mW/cm2 at the substrate. For photopatterning 
of biomolecules, a chromium-coated glass photomask with 500-μm square features separated by 
500 µm, or a relief mask presenting 800-µm circles with 200-µm spacing, was placed onto the 
back of the substrate and irradiated for the following times: 5 min for ConA-biotin and 1 min for 
P-selectin. 
Following UV exposure, the flow chamber assembly was immersed in a rinse solution 
and the substrate was separated from the flow chamber device. The following rinse solutions 
were utilized: 0.5% (v/v) Tween 20 in PBS buffer for substrates presenting ConA-biotin and 
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fibronectin; and 0.5% (v/v) Tween 20 and 1% (w/v) BSA in Dulbecco’s PBS with Ca2+ and Mg2+ 
for substrates presenting P-selectin.  
2.4.6 Fluorescence imaging of substrates presenting photoimmobilized biomolecules 
Photopatterned substrates were blocked with 1% BSA in PBS or HEPES overnight 
followed by incubation with fluorescently labeled binding partners and visualization with a 
fluorescence slide scanner (GenePix 4000B, MDS Analytical Technologies) to obtain 
fluorescence intensity line scans. For the visualization of immobilized ConA-biotin, substrates 
were incubated for 1 h in a solution of streptavidin−AlexaFluor647 conjugate (0.05 μg/mL, 
Invitrogen) in 1% BSA/HEPES. For substrates with two-component mannan and P-selectin 
immobilization, slides were incubated for 1 hr in a solution of ConA-biotin (0.1 μg/mL), 
streptavidin−Cy3 conjugate (0.05 μg/mL, Invitrogen), mouse anti-human P-selectin (0.5 μg/mL, 
R&D Systems, clone 9E1), and AlexaFluor647-conjugated rabbit anti-mouse IgG (1 μg/mL, 
Invitrogen) in 1% BSA/HEPES. Substrates presenting P-selectin for native-ligand binding 
studies were incubated overnight in a solution containing: native ligand PSGL-1 (8 µg/mL, Fc 
chimera, R&D Systems), mouse anti-human IgG (4 µg/mL, Abnova), and AlexaFluor647-
conjugated goat anti-mouse IgG (2 µg/mL, Invitrogen), in 1% BSA/PBS with Ca2+ and Mg2+. 
Substrates were rinsed in PBS, water, dried under a stream of nitrogen, and imaged on a 
fluorescence slide scanner. The specific ligand-binding ability of P-selectin is demonstrated by 
the fact that incubation in the same solution lacking PSGL-1 results in baseline fluorescence 
levels in the resulting images (data not shown).  
2.4.7 Quantitative determination of immobilized protein site density 
To determine protein loading on BP-modified substrates under various 
photoimmobilization conditions, a radioimmunoassay using an [125I]-labeled binding partner was 
performed to analyze photopatterned protein substrates. In an effort to establish a relationship 
between the site density from the radioimmunoassay and the fluorescence intensity (F.I.), 
identical substrates were created and analyzed in parallel using both fluorescence and 
immunological methods, and the resultant data were correlated. A rectangular parallel-plate flow 
chamber was assembled with a BP-modified glass substrate (as described above). The assembled 
device was positioned face-down, allowing for illumination through the back of the substrate 
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beneath the UV LED array source, which was configured to an output of power of 17 mW/cm2. 
A total of 8 substrates were prepared for each of the following six irradiation time points in the 
presence of ConA-biotin (5 µg/mL): 5, 15, 30, 60, and 120 sec. BP-modified substrates that 
never contacted ConA-biotin were used as controls. Four of the eight replicates at each exposure 
time were analyzed for F.I., as described above. The remaining four replicates were subjected to 
a radioimmunoassay for site density quantitation.  
[125I]-labeled streptavidin was generated by a standard protein iodination technique. 
Streptavidin (10 mg/mL, Pierce) was placed into the bottom of tube pre-coated with Pierce 
Iodination Reagent, along with 125I (5 µCi/µg, in 10-8 M NaOH, Perkin-Elmer), followed by 
incubation at room temperature for 10 min with shaking. The solution was then purified using a 
Bio-Spin 6 purification column (Bio-Rad). The percentage of excess 125I remaining in the protein 
solution was determined following a standard protocol for thin layer chromatography on 
Whatman filter paper.27 The concentration of material obtained after purification was determined 
using a Bradford assay. Slides presenting ConA-biotin were incubated with saturating 
concentrations of [125I]-labeled SA (0.05 µg/mL) in 1% BSA/PBS for 1 hr, rinsed in PBS, 
purified water, and dried under a stream of nitrogen. Slides were cut into four pieces and each 
piece placed into a scintillation tube with 1 mL of scintillation fluid (ScintiSafe Econo 1, Fisher 
Scientific). The radioactivity count for all the sample tubes was determined using a scintillation 
counter (Beckman LS 6500 Liquid Scintillation Counter, Beckman Coulter), and reported in 
units of counts per min (CPM). The number of radioactive molecules bound per area 
(molecules/µm2) was then determined by comparison of the CPM obtained from the slides to a 
standard curve of [125I]-labeled streptavidin standards of known concentration. Plots of F.I. vs. 
exposure time, and CPM vs. exposure time were combined to establish a correlation between F.I. 
and the density of immobilized biomolecules.  
2.4.8 Cell adhesion and rolling studies 
HL-60 cells (gift from the Hergenrother group at UIUC, or purchased from ATCC) were 
cultured in RPMI 1640 supplemented with penicillin (100 U/mL), streptomycin (100 μg/mL), 
and 10% fetal bovine serum (SCS Cell Media Facility, UIUC). Photopatterned P-selectin 
substrates were prepared as described above.  Substrates were rinsed and soaked overnight in 
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PBS containing 0.2% Pluronic F127 and 1% BSA. Substrates were then rinsed three times in 
water and placed into a cell culture dish (100 mm x 20 mm). Cells were fluorescently labeled 
using AlexaFluor488 carboxylic acid succinimidyl ester (Invitrogen) and seeded onto substrates 
in PBS at a concentration of 5 x 106 cells/mL and incubated at 4 ºC for 2 hr. The solution was 
aspirated off and the substrates were rinsed in PBS to remove non-specifically bound cells. The 
resulting patterns of cells were visualized using a fluorescence microscope (Leica DM 6000 
Upright Microscope, Leica Microsystems). 
For cell patterning demonstrations, photopatterned P-selectin gradient substrates were 
prepared as described, rinsed and sonicated for 30 min in 0.2% Pluronic F127 in PBS, and 
blocked overnight in 0.2% Pluronic F127 and 1% BSA in PBS. Cells were seeded onto 
substrates at 5 × 106 cells/mL in PBS and incubated at 4 °C for 2 hr. Nonadhered cells were 
aspirated off after gentle rinsing with PBS, and the resulting cell gradients were imaged using an 
optical microscope (Zeiss 40C Invertiskop, Carl Zeiss Inc.). 
For HL-60 cell rolling studies, a 6-mm P-selectin gradient was prepared as described and 
assembled with the parallel plate flow chamber. Cells were resuspended in cell media at 5 × 
105 cells/mL and flowed through the chamber at 50 μL/min, yielding an applied shear stress of 
0.24 dyn/cm2. Shear stress was calculated using the equation Ƭ = 6μQ/a2b, where μ is the 
apparent viscosity of the media, Q is the volumetric flow rate, a is the height of the flow 
chamber, and b is the width of the flow chamber. Cell rolling videos were recorded with a digital 
camera, and the velocity of rolling cells was determined with ImageJ (National Institutes of 
Health). 
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Chapter 3 
 
 
Probing Dynamic Cell-Substrate Interactions using Photochemically 
Generated Surface-Immobilized Gradients: Application to Selectin-
Mediated Leukocyte Rolling 
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3.1 Introduction 
Numerous cellular processes depend on a cell’s ability to sense and respond to 
biomolecular gradient cues. Embryonic development, neuronal guidance, angiogenesis, wound 
healing, inflammation, and cancer/metastasis are among the complex physiological phenomena 
that are regulated and/or guided by spatial variation in the concentrations of ligands encountered 
either in the solution phase or presented as immobilized gradients within the cellular 
microenvironment (i.e., adjacent cells or the extracellular matrix).1 In order to experimentally 
parse out the detailed contributions of immobilized ligand density on cell behavior, substrates 
that present biomolecular gradients on surfaces are of fundamental interest for in vitro assays that 
enable the investigation of cell migration and polarization in response to immobilized protein 
concentration.2 Of even greater interest are in vitro platforms that enable multi-parameter studies 
that systematically address the combined effects of multiple stimuli, such as the density of 
multiple biomolecules, topography, or shear stress, amongst others, on cell behavior.3 
Many approaches have been developed to generate biomolecular surface gradients, 
including the use of microfluidics followed by surface attachment,2a,4 electrochemical desorption 
of self-assembled monolayers on gold,5 photochemical surface deproctection to reveal reactive 
functional groups,6 and diffusion-guided  surface adsorption.7 Each of these techniques have 
inherent strengths and limitations, as detailed in Chapter 1.  
The approach involves surface functionalization of glass to present a well-known 
photocrosslinking molecule, benzophenone (BP).8 Solutions containing the biomolecule of 
interest are introduced to the substrate through a flow chamber and immobilized as UV light 
(351.1-363.8 nm) induces the formation of new C-C bonds between the BP molecules on the 
surface and the proteins. This approach was previously shown by our lab to be useful for the 
generation of single- and multi-component geometric patterns and spatial concentration gradients 
composed of both proteins and carbohydrates.9 In choosing this particular gradient generation 
approach, I reasoned that the overall simplicity, biomolecular generality, and capability to 
generate complex, multi-component substrates for biointerface studies would make this a broadly 
applicable platform for researchers from many different fields possessing varying degrees of 
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familiarity with the advanced surface chemistries and microfabrication techniques utilized in 
other gradient generation methodologies.  
As a proof-of-principle demonstration of this technique, I was interested in applying 
surface-immobilized gradients to achieve a better understanding of the process of leukocyte 
recruitment, the first step in the inflammatory response. Over the past several decades, numerous 
biomolecules involved in leukocyte trafficking have been identified and characterized. Among 
these are a family of molecules known as selectins, which are membrane-bound glycoproteins 
presented on leukocytes (L-selectin) and inflamed endothelial cells (P-selectin, E-selectin).10 The 
role of selectins is to mediate the initial flow-dependent tethering and rolling of leukocytes on 
vascular surfaces.11 Following selectin-mediated rolling, additional biomolecular interactions 
take place with other endothelial-expressed proteins and enzymes that ultimately lead to 
leukocyte arrest, diapedesis and migration through the tissue to the site of injury or infection.12 
Properly regulated inflammatory and immune responses are essential for health and survival, but 
if left unchecked, can result in a variety of diseases such as rheumatoid arthritis, asthma, 
psoriasis, Crohn’s disease, thrombotic disorders, and autoimmune disease.13  A more complete 
understanding of the molecular basis of leukocyte recruitment could lead to the development of 
more effective therapeutics for dysregulated inflammation.  
Previous studies have shown that selectin-mediated rolling under conditions of 
physiological shear stress can be studied in an in vitro flow assay format, yielding new insights 
into the biophysical phenomena underlying the first step of leukocyte recruitment.14 In vitro 
leukocyte flow assays, however, typically employ surfaces presenting non-specifically adsorbed 
proteins15,16 that are susceptible to changes over time,17 or utilize confluent endothelial cell 
monolayers18 that express multiple relevant ligands but offer little control over ligand site 
density.  
As schematically illustrated in Figure 3.1, substrates presenting photochemically 
immobilized gradients of P-selectin and PSGL-1 were generated, characterized, and employed in 
leukocyte flow assays to determine how various selectin-ligand interactions affect the rolling 
behavior of two leukocyte cell lines, HL-60 promyelocytes and Jurkat T lymphocytes. Cells were 
perfused across substrates presenting immobilized protein under conditions of physiological wall 
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shear stress. Videos were acquired at several positions across the gradient surface and analyzed 
to assess the combined effect of protein site density and wall shear stress on the number and 
velocity of rolling cells. By analyzing cell behavior at each combination of site density and shear 
stress, the interplay between immobilized protein density and shear stress was observed. This 
simple gradient generation approach will allow for the interrogation of the complex mechanisms 
involved in the biological processes involved in leukocyte rolling in vivo and further elucidate 
the interplay between substrate composition and environmental conditions.  
 
In this study, I describe a facile, molecularly general method for generating model 
substrates that present covalently immobilized biomolecules at defined and varied site densities. 
Furthermore, I demonstrate that gradient substrates presenting proteins over a wide range of site 
densities allow data-rich information to be collected from a single substrate in a short time. This 
presents an additional advantage over previous approaches which utilize substrates limited to a 
 
Figure 3.1 A schematic representation of the process by which surface-immobilized gradients 
on benzophenone (BP)-modified substrates are generated, characterized, and applied to multi-
parameter leukocyte flow investigations. 
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single homogeneous presentation of a protein of interest and require multiple substrates to probe 
the concentration dependence of leukocyte rolling.  
3.2 Results and Discussion 
In this proof-of-principle study, I demonstrate that surface-immobilized biomolecular 
gradients generated using BP-modified substrates can be tailored to present protein site densities 
in a controlled manner and can be applied to leukocyte flow assays. Previous reports of 
leukocyte flow assays have typically employed substrates that present adsorbed proteins at a 
uniform site density. The advantages of utilizing photochemically immobilized protein gradients 
over adsorbed protein substrates are increased biomolecule attachment stability (due to a 
covalent linkage of proteins to the surface) and the ability to present ligands at controllably 
varied site densities on a single substrate. This provides a more direct route to conducting 
comprehensive investigations to assess the effects of various combinations of shear stress and 
site density on cell behavior using a single substrate, compared to many different substrates that 
each present only a single immobilized density. In this way, large amounts of data can be 
acquired from a single experiment, minimizing the amount of materials and time that are 
required for a multi-parameter analysis of selectin-mediated rolling.  
 
3.2.1 Characterization of BP-modified substrates 
Three batches of BP-modified substrates were generated (Table 3.1). Following each 
chemical derivatization, substrates were characterized with contact angle goniometry. The 
 
Table 3.1  Summary of contact angles following silanization with TESA and 
functionalization with benzophenone (BP). The contact angles reported for each batch are the 
average (± standard deviation) of at least four substrates.  
 
H2O Contact 
Angle, 
Batch 1
H2O Contact 
Angle,
Batch 2
H2O Contact 
Angle,
Batch 3
Average of 3 
batches
TESA silanization 48.0 (±1.4) 42.7 (±1.1) 45.2 (±2.6) 45.2 (±2.6)
+BP 57.5 (±7.7) 59.6 (±0.9) 57.3 (±3.9) 58.1 (±3.9)
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contact angle after silanization was 45.2 (± 2.6)°. After functionalization with BP, the contact 
angle increased to 58.1 (± 3.9)°.  
 
3.2.2 Quantitative determination of immobilized protein site densities 
Data from radioimmunoassays and fluorescence assays are plotted to show the 
relationship between F.I. and site density, as shown in Figure 3.2. Under the conditions used, I 
observed that the relationship between the F.I. and corresponding radioactivity signal (converted 
from cpm to site density using a standard curve) was linear for each set of immobilized protein 
substrates. The reported site densities are an estimate based on the ability of antibodies to detect 
the proteins. For simplicity, I assume a 1:1 binding relationship between the [125I]-labeled 
secondary polyclonal antibody (pAb) and primary monoclonal antibody (mAb), which likely 
results in an overestimate of protein loading, since each primary mAb might be recognized by 
multiple secondary [125I]-labeled pAbs. I also assume a 1:1 binding relationship between the 
Conditions for generation of one-component gradients used in Jurkat cell flow assays 
Protein 
concentration 
(µg/mL) 
power 
(mW/cm2) 
total 
exposure 
time (sec) 
gradient 
size 
(mm) 
size of gradient 
used in assay 
(mm) 
# positions 
analyzed in 
assay 
P-selectin 5 14 24 4.8 2.4 8 
PSGL-1 10 14 24 4.8 3 7 
 
Conditions for generation of one-component gradients used in HL-60 cell flow assays 
Protein 
concentration 
(µg/mL) 
power 
(mW/cm2) 
total 
exposure 
time (sec) 
gradient 
size (mm) 
size of 
gradient used 
in assay (mm) 
# positions 
analyzed in 
assay 
P-selectin 10 14 30 4.8 4.2 10 
PSGL-1 10 14 24 4.8 4.2 7 
 
Table 3.2  Summary of gradient generation conditions used to generate one-component 
gradients of P-selectin and PSGL-1. 
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primary mAb and the immobilized surface proteins, although each primary mAb has two antigen 
binding sites. Overall, the effective site density is probably lower than that determined from the 
radioimmunoassay since proteins are randomly orientated on the surface and therefore not all are 
able to be recognized by cellular receptors. However, similar methods and assumptions have 
been previously made for substrates used in quantitative selectin-ligand assays.19 
 
Figure 3.2  The relationship between fluorescence intensity and site density was determined 
for photoimmobilized P-selectin (red) and PSGL-1 (green) on BP-modified substrates. 
Substrates were generated in triplicate via flood UV exposures (four different exposure times 
ranging from 10 to 180 sec) in the presence of protein solution, resulting in homogeneous 
substrates presenting a wide range protein site density levels. Fluorescence measurements 
were acquired after incubating substrates with fluorescently labeled antibodies. For site 
density determination, substrates were incubated with saturating concentrations of primary 
monoclonal antibody (mAb) and [125I]-labeled secondary polyclonal antibody (pAb). Control 
substrates were used to account for non-specific mAb and pAb binding. Data is plotted as the 
average (± 95% C.I.) for n=3 substrates. 
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Substrates for Jurkat cell flow assays 
 
Substrates for HL-60 cell flow assays 
P-selectin 
site density 
standard 
deviation approximation 
 
P-selectin 
site density 
standard 
deviation approximation 
(molecules/µm2) 
 
(molecules/µm2) 
2392.03 364.52 2400 
 
958.43 87.69 1000 
2180.13 502.35 2200 
 
770.42 152.76 800 
1782.28 525.53 1800 
 
657.79 130.43 650 
1384.13 396.81 1400 
 
545.16 102.76 550 
1026.76 311.67 1000 
 
448.74 84.59 450 
669.1 92.73 650 
 
352.32 61.69 350 
425.96 28.84 450 
 
286.76 50.21 280 
182.81 12.38 180 
 
221.19 0.73 220 
    
182.78 22.78 180 
    
144.37 17.99 140 
       PSGL-1 site 
density 
standard 
deviation approximation 
 
PSGL-1 site 
density 
standard 
deviation approximation 
(molecules/µm2) 
 
(molecules/µm2) 
5899.34 1313.66 6000 
 
4339.32 1032.91 4500 
4646.76 777.97 5000 
 
3860.19 971.11 4000 
3927.47 712.62 4000 
 
3470.98 767.19 3500 
3424.61 721.77 3500 
 
2697.33 738.54 2500 
2581.96 544.16 2500 
 
1718.97 516.5 1500 
1739.31 365.04 1800 
 
1125.06 397.79 1000 
836.41 175.5436 800 
 
123.08 84.66 100 
 
Table 3.3  Summary of data and respective approximations from one-component gradients of 
P-selectin and PSGL-1 on BP-modified substrates. Protein site density was determined by 
converting data from fluorescence assays to site density using data from fluorescence-
radioactivity correlation studies (see Figure 3.2). 
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3.2.3 Generation and characterization of linear one-component gradients 
The goal in preparing one-component gradient substrates for leukocyte flow assays was 
to incorporate biomolecules that are known to be involved in the initial steps of leukocyte 
recruitment. The first step of leukocyte recruitment is rolling along the endothelium, which is 
facilitated by selectin-ligand interactions. In these studies, I generated and characterized one-
component gradients of P-selectin and PSGL-1 and applied them to leukocyte flow assays. 
Conditions for gradient generation were optimized by adjusting protein concentration, exposure 
time and light intensity, to yield linear slopes encompassing a large range of protein site 
densities, which are detailed below. The plots in Figure 3.3 show linescans from two or three 
replicate substrates for each protein. The conditions utilized for P-selectin and PSGL-1 gradients 
were optimized for each protein. For clarity, I report the values as approximations of the 
precisely determined values (Table 3.3). Gradient substrates made in parallel with those used in 
 
Figure 3.3  Linescans for one-component gradient substrates prepared for flow assays with 
HL-60 cells. BP-modified substrates present immobilized (a) P-selectin and (b) PSGL-1 on 
BP-modified substrates. Gradients were characterized in a fluorescence assay and 
fluorescence data was converted to site density using the results from the fluorescence-
radioactivity correlation studies.   
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cell rolling experiments were characterized in a fluorescence assay and the results converted to 
site density using the appropriate linear relationship between F.I. and site density for each 
protein. The average site density at various positions along the gradient was determined for a 
region the size of the field of view of a 20x microscope objective.  
3.2.4 Leukocyte flow assays 
It is well-established that interactions between the selectins (P-, E-, and L-selectin) and 
their respective ligands facilitate leukocyte rolling, both in vitro and in vivo.11d P-selectin is 
responsible for initiating tethering and rolling of leukocytes on the blood vessel endothelium,20 
while L-selectin is expressed on most leukocytes and is able to bind to ligands on the 
endothelium21 as well as to PSGL-1 presented on other cells.22 This latter process is known as 
secondary tethering and enables rolling leukocytes to recruit additional leukocytes to the 
inflamed endothelium. In these studies, I generated substrates presenting varied site densities of 
P-selectin and PSGL-1 and applied them to leukocyte flow assays.  
HL-60 cells were found to tether to and roll on P-selectin substrates over a wide range of 
site densities and wall shear stresses. Jurkat cells also tethered to and rolled on immobilized P-
selectin, as well as PSGL-1, over a range of site densities and shear stresses. HL-60 cell rolling 
was not observed on PSGL-1 substrates (data not shown), which is consistent with literature 
reports that show low L-selectin expression on HL-60 cells.23 
In general, I found that a minimum level of wall shear stress, commonly referred to as the 
shear threshold,15,24 was required for selectin-mediated cell rolling to be initiated and sustained, 
and was also affected by the underlying site density of immobilized protein. A lack of cell rolling 
under a particular set of conditions is represented by the absence of that data point. In all cases, 
data from three replicate substrates is plotted as the average (±SEM), unless otherwise noted. 
Alongside each 2D plot, the average rolling velocities and cell flux are plotted in 3D surface 
plots (without error bars for clarity) to present the combined effects of site densities and shear 
stress on cell rolling velocity as an interaction landscape. 
 Neither cell type was found to interact with BSA-blocked BP-modified substrates, 
confirming that leukocyte rolling on gradient substrates were indeed the result of specific  
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Figure 3.4  Results from initial attachment assays of HL-60 cells on immobilized P-selectin. 
HL-60 cells were perfused over one-component P-selectin gradient substrates at shear stresses 
ranging from 0.062 to 2.17 dyn/cm2. 2D data plots and 3D surface plots show the average cell 
(a) rolling velocity and (b) rolling flux plotted as a function of shear stress and P-selectin site 
density. At low site densities (140 and 180 molecules/µm2), rolling velocity increased sharply 
as a function of shear stress, while at all higher site densities analyzed, the rolling velocity 
leveled off beyond 0.93 dyn/cm2. At site densities of 140 and 180 molecules/µm2, 
significantly fewer rolling cells were observed compared to at higher site densities (p<0.05), 
while increasing the site density from 280 to 1000 molecules/µm2 had no significant effect on 
rolling flux at shear stresses ≥ 0.16 dyn/cm2. The mean rolling velocity or rolling flux was 
determined for each substrate, and the means from three substrates were averaged and plotted 
as the average (±SEM). Open data points represent the average (±range) of n=2 substrates.  
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interactions with the immobilized protein of interest. When Jurkat cells were incubated with a 
function-blocking mAb against L-selectin (10 µg/mL), cell rolling on immobilized PSGL-1 
substrates was absent under all conditions of wall shear stress investigated. Additionally, when 
P-selectin substrates were incubated with a function-blocking mAb (20 µg/mL), cell rolling for 
both cell types was completely eliminated (data not shown). 
3.2.4.1 P-selectin-mediated rolling of HL-60 cells 
P-selectin substrates for HL-60 flow assays presented site densities ranging from 140 to 
1000 molecules/µm2 (Figure 3.3a). Cell rolling was observed over the entire range of site 
densities and the shear threshold was met starting at a shear stress of 0.062 dyn/cm2 (10 µL/min). 
I found that as site density decreased, cell rolling occurred over a smaller range of shear stresses. 
At site densities of 140 and 180 molecules/µm2, cell rolling was observed from the shear 
threshold value up to 0.62 and 0.93 dyn/cm2, respectively, while at site densities ≥ 280 
molecules/µm2, cell rolling was observed up to 2.17 dyn/cm2 (Figure 3.4a). Above 2.17 dyn/cm2, 
HL-60 cell rolling was not observed at any of the site densities analyzed.  
Rolling velocity data for HL-60 cells on P-selectin gradient substrates are represented in 
a 3D surface plot (Figure 3.4a), showing the combined effect of site density and shear stress on 
rolling velocity. Decreasing the site density from 220 to 140 molecules/µm2 resulted in an 
increase in the average rolling velocity, which I presume is because a lesser number of receptor-
ligand interactions leads to faster rolling. I speculate that saturation of cell surface-expressed 
PSGL-1 occurs above 220 molecules/µm2, resulting in an average cell rolling velocity that is not 
significantly affected by shear stress. Overall, HL-60 cell rolling velocity increased as shear 
stress increased, and the effect was most pronounced at lower site densities.  
Figure 3.4b shows the effect of shear stress and site density on cell rolling flux. 
Consistent with the cell rolling velocity data presented in Figure 3.4a, increasing the site density 
above 220 molecules/µm2 at a given shear stress did not significantly affect rolling flux. The 
effect of shear stress at a given site density, however, exhibited the following trend: At site 
densities of 220 molecules/µm2 and higher, rolling flux remained constant from 0.062 dyn/cm2 to 
0.93 dyn/cm2, above which it dropped until cells were no longer observed to roll. Conversely, at 
the lowest site densities analyzed (140 and 180 molecules/µm2), rolling flux was unaffected by  
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increasing shear stress up to 0.93 and 1.55 dyn/cm2, respectively, above which cells were no 
longer observed to roll. Overall, fewer cells (~3-fold less) were found to roll on the lowest site 
densities analyzed (140 and 180 molecules/µm2), compared to at site densities ≥ 280 
molecules/µm2. 
3.2.4.2 P-selectin-mediated rolling of Jurkat T cells 
P-selectin-mediated cell rolling was also assessed for Jurkat T cells. P-selectin substrates 
for Jurkat flow assays presented site densities ranging from 140 to 1000 molecules/µm2 (Figure 
3.5a). Many trends were similar to those observed with HL-60 cells, including an overall positive  
 
Figure 3.5  One-component gradients of (a) P-selectin and (b) PSGL-1 on BP-modified 
substrates were generated and characterized by converting data from fluorescence assays to 
site density using the results from fluorescence-radioactivity correlation studies (Figure 3.2). 
For substrates used in Jurkat flow assays, immobilized protein site densities ranged from 
approximately 180 to 2400 and 800 to 6000 molecules/μm2 for P-selectin and PSGL-1, 
respectively.  
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Figure 3.6  Results from initial attachment assays of Jurkat cells on immobilized P-selectin.  
(a) A 3D surface plot of rolling velocity as a function of shear stress and P-selectin site 
density reveals that increasing shear stress resulted in an overall increase in rolling velocity.  
However, the velocity of rolling cells at a given shear stress was largely unaffected by 
increasing site density, except at 0.47 dyn/cm2, in which case rolling velocity was higher at a 
site density of 650 molecules/µm2 compared to 1800 or 2200 molecules/µm2 (*, p<0.05).  (b) 
Rolling flux was greatest at higher site densities and lower shear stresses and decreased with 
increasing shear stress, except at the lowest site densities analyzed (650 and 1000 
molecules/µm2) at which rolling flux was steady over the range of shear stresses under which 
cell rolling was observed.  The mean rolling velocity or rolling flux was determined for each 
substrate, and the means from three substrates were averaged together and plotted as the 
average (±SEM). Open data points represent the average (±range) of n=2 substrates.  
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correlation between cell rolling velocity and shear stress (Figure 3.6a), and an inverse correlation 
between shear stress and rolling flux (Figure 3.6b). However, at a given shear stress, rolling 
velocity was largely unaffected by increasing site density, except at 0.47 dyn/cm2, at which cells 
rolled at a significantly higher rolling velocity at 650 molecules/µm2 compared to at 1800 or 
2200 molecules/µm2 as illustrated in Figure 3.6 (p<0.05). Notably, the range of average rolling 
velocities for Jurkats on P-selectin is smaller and lower than that of HL-60 cells (approximately 
3 - 12 µm/sec for Jurkat cells, compared to 1 - 50 µm/sec for HL-60 cells).  
 Similar to HL-60 cells, the number of rolling Jurkat cells on immobilized P-selectin 
decreased with increasing shear stress and, under certain shear stress conditions, increased with 
site density. More specifically, the number of rolling cells on a P-selectin site density of 1800 
molecules/µm2 was significantly higher than on 650 molecules/µm2 in the range of 0.16 to 0.47 
dyn/cm2 (p<0.05). At shear stresses greater than 0.47 dyn/cm2, increasing site density had no 
effect on rolling flux (Figure 3.6b).  
3.2.4.3 PSGL-1-mediated Jurkat cell rolling 
To probe L-selectin-mediated rolling of Jurkat cells, substrates presenting immobilized 
PSGL-1 ranging from 800 to 6000 molecules/µm2 were utilized in leukocyte flow assays with 
Jurkat cells. On PSGL-1, the shear threshold for rolling was found to be 0.31 dyn/cm2, compared 
to 0.16 dyn/cm2 on P-selectin. Overall, average Jurkat cell rolling velocities on PSGL-1 were 
approximately 20-fold higher than on immobilized P-selectin (98.11-227.94 µm/sec on PSGL-1, 
compared to 2.40-11.91 µm/sec on P-selectin). This is consistent with previous reports which 
describe L-selectin-mediated rolling velocities are much higher that P- or E-selectin-mediated 
cell rolling due to differences in receptor-ligand kinetics.25 The average rolling velocity 
decreased with increasing site density at a given wall shear stress, and increasing shear stress 
above 0.47 dyn/cm2 had no significant effect on rolling velocity at a given site density (Figure 
3.7a). At positions presenting PSGL-1 at site densities from 2500 to 6000 molecules/µm2, cell 
rolling was observed from 0.31 to 1.55 dyn/cm2, while at a site density of 1800 molecules/µm2, 
rolling was observed from 0.16 to 0.93 dyn/cm2. Comparatively, P-selectin-mediated Jurkat cell 
rolling occurred over a smaller range of shear stresses: Cell rolling was observed from 0.16 to  
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Figure 3.7  Results from initial attachment assays of Jurkat cells on immobilized PSGL-1.  
(a) Overall, cell rolling velocity was highest at lower site densities. At site densities ≥3500 
molecules/µm2, rolling velocity increased with increasing shear stress up to 1.55 dyn/cm2.  As 
site density decreased below 3500 molecules/µm2, the range of shear stresses at which cell 
rolling occurred decreased, and increasing the shear stress had no effect on the rolling 
velocity.  (b) The rolling flux of cells was affected by site density in a manner that was 
dependent on the shear stress.  Linear regression and correlation analyses reveal that at 0.62 
dyn/cm2, the rolling flux increased most sharply as site density increased compared to at all 
other shear stresses analyzed. At all site densities analyzed, rolling flux increased as shear 
stress increased from 0.47 to 0.62 dyn/cm2, and decreased thereafter. The mean rolling 
velocity or rolling flux was determined for each substrate, and the means from three 
substrates were averaged together and plotted as the average (±SEM). Open data points 
represent the average (±range) of n=2 substrates.  
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0.62 dyn/cm2 on site densities ranging from 1000 to 2200 molecules/µm2, and from 0.31 to 0.62 
dyn/cm2 on a site density of 650 molecules/µm2 (Figure 3.7). 
 Data presented in Figure 3.6b show that Jurkat cell rolling flux on immobilized PSGL-1 
substrates increased linearly as a function of site density in a manner that was dependent on the 
applied shear stress. This is evidenced by the slopes of the linear regression analyses of rolling 
flux vs. PSGL-1 site density. In all cases, a positive correlation was found (p<0.05, r2= 0.95, 
0.98, and 0.86 for 0.47, 0.62, and 0.93 dyn/cm2, respectively), showing that Jurkat cell rolling 
flux on PSGL-1 increased with increasing site density at a given shear stress. Interestingly, the 
slope of the linear fit was highest for data collected at 0.62 dyn/cm2, revealing that at this level of 
shear stress, site density had a greater effect on rolling flux compared to higher or lower shear 
stresses (0.47 or 0.93 dyn/cm2).  
3.2.4.4 HL-60 cell rolling and adhesion on two-component substrates of ICAM-1 and P-selectin   
BP-modified substrates were tailored to present two biomolecules, intercellular adhesion 
molecule-1 (ICAM-1, R&D Systems) and P-selectin, and were utilized to investigate the effect 
of ICAM-1 density on cell rolling and adhesion (Figure 3.8).   Briefly, a BP-modified substrate 
as assembled into the flow chamber and a solution of ICAM-1 (5 µg/mL) was introduced into the 
chamber.  A relief mask with an array of circles (800-µm diameter, 200-µm spacing) was placed 
on the substrate, and a 5-mm gradient was generated over the array mask by programming the 
shutter to move a total of 5 mm over the duration of the UV exposure (12 sec, 14 mW/cm2, as 
discussed above).  PBS was flowed through the chamber to rinse out residual protein solution 
(400 µL/min for 3 min), then a solution of P-selectin (1.25 µg/mL) was introduced into the 
chamber and was photopatterned through the array mask for 5 sec (14 mW/cm2). 
 In this manner, substrates were tailored to present a gradient of an adhesive protein, 
ICAM-1, amidst a uniform density of P-selectin.  Substrates were characterized in a fluorescence 
immunoassay (Figure 3.8) and were utilized in leukocyte flow assays.  HL-60 cells were flowed 
over the substrate at a shear stress of 0.23 dyn/cm2, and the total numbers of rolling and adherent 
cells were determined as a function of ICAM-1 ligand density.  At low levels of ICAM-1, the 
majority of cells are found to roll on the substrate, with less than 30% of interacting cells leading 
to firm adhesion.  At high levels of ICAM-1, the majority of interacting cells are found to  
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convert to firm adhesion.  On substrates presenting comparable levels of ICAM-1 in the absence 
of P-selectin, no cells were found to interact with the substrate (data not shown), which is 
consistent with previous literature reports that demonstrate that selectin-mediated rolling is a 
prerequisite for ICAM-1-mediated cell adhesion.26 
3.2.5 Summary 
In these studies, biomolecular gradient generation was performed on two different days 
for flow assays involving HL-60 cells and Jurkat cells. The range of protein site densities 
presented on the substrates generated for this study is comparable to the values that have been 
 
Figure 3.8  Substrates presenting ICAM-1 and P-selectin in an 800-µm circle array were 
characterized and utilized in leukocyte flow assays to assess the interplay of rolling and 
adhesion. (a) A fluorescence image of the two-component gradient substrate (top: ICAM-1, 
Cy5, red; middle: P-selectin, Cy3, green; bottom: overlay), and (b) the corresponding 
fluorescence linescans. (c) A greater percentage of cells are found to adhere to the substrate in 
areas with high levels of ICAM-1, under conditions of shear stress (0.23 dyn/cm2). Data 
points represent the total percentage of rolling and adhered cells in three different rows of 
circles on a representative substrate. Scale bar: 800 µm. 
 
 
0 1 2 3 4 5 6
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (a
.u
.)
Relative Position (mm)
 ICAM-1
 P-selectin
1 2 3 4 5
0.2
0.3
0.4
0.5
0.6
0.7
0.8
%
 o
f I
nt
er
ac
tin
g 
C
el
ls
Relative ICAM-1 Density
 % Rolling
 % Adhered
Low Med High
(b) (c)(a)
64 
 
previously reported in the literature for applications in leukocyte flow assays. Specifically, Brunk 
and Hammer19 report microsphere rolling on E-selectin substrates ranging from 1400 to 3500 
molecules/µm2 and Alon, et al.27 used P- and E-selectin substrates of 500 and 650 
molecules/µm2 for investigating T cell rolling. Important insights have been gleaned from these 
previous studies conducted at densities comparable to those generated in this paper.  
I found that both HL-60 and Jurkat cells rolled on immobilized P-selectin gradients, 
while only Jurkat cells rolled on immobilized PSGL-1, consistent with literature reports of low 
L-selectin expression on HL-60 cells.24 In addition, other trends observed in the cell rolling 
velocity and rolling flux data presented here are consistent with previous reports. For example, 
Lawrence, et al. studied HL-60 cell rolling on immobilized P-selectin24 and observed, similar to 
these findings, that rolling flux is enhanced by increasing fluid shear up to a certain level, above 
which it decreases until cell rolling ceases to occur. In another study, Alon, et al. analyzed HL-
60 cell rolling on an uncharacterized substrate of immobilized P-selectin up to wall shear stress 
levels of approximately 3 dyn/cm2, observing a plateau in rolling velocity as shear stress was 
increased.27 This is similar to the results for HL-60 cells rolling at P-selectin site densities of ≥ 
280 molecules/µm2. Additionally, for each selectin-ligand interaction probed, I found that a 
minimum shear threshold level was required in order for cells to roll on the surface, and that the 
threshold level was different for each protein, and in some cases for each ligand site density. 
As noted in the literature,11d an interesting characteristic of selectin-mediated rolling, as 
opposed to rolling mediated by immobilized antibodies, is the ability to maintain near-constant 
cell rolling velocities even as cells are subjected to increasing levels of shear stress. Observed in 
both in vivo28 and in vitro29 studies, this is understood to be the result of an “automatic braking 
system,” which comes from a combination of cellular features (i.e., deformability and extrusion 
of membrane tethers) and certain molecular features of selectins and their corresponding 
ligands.11d When a cell comes into contact with a surface, there are repulsive forces that may be 
overcome by increasing shear stresses, enabling increased bond formation. In the data presented 
here, this trend is most clearly seen in initial attachment assays for HL-60 cells on P-selectin (at 
site densities ≥280 molecules/µm2). Rolling velocities were seen to plateau instead of increasing 
linearly in proportion to increasing shear stress (Figure 3.4a). Although rolling velocity was not 
affected by increasing shear stress from 0.93 to 2.17 dyn/cm2, the number of rolling cells 
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decreased over this range of shear stresses (Figure 3.4b). It appears, then, that shear stress affects 
the ability of HL-60 cells to tether to P-selectin in order to initiate rolling. However, once cells 
are rolling, shear stress does not affect the velocity at which they will roll. Initial attachment 
assays assessed the ability of cells to tether to the surface and initiate rolling in the presence of a 
given shear stress. The data suggests that the velocity of cells rolling on P-selectin remains 
constant over a wide range of wall shear stresses when the cells initiate rolling at each level of 
shear stress evaluated (Figure 3.4a). 
  For P-selectin-mediated Jurkat rolling, only at higher site densities (≥1400 
molecules/µm2) did the rolling velocity of cells plateau with increasing shear stress (Figure 3.6). 
PSGL-1-mediated Jurkat cell rolling velocities (Figure 3.7a) show this same trend at site 
densities ≥ 3500 molecules/µm2.  
 I also found that HL-60 and Jurkat cells show differences in cell rolling behavior on 
immobilized P-selectin substrates. Comparing data in Figure 3.6b and Figure 3.4b, it is seen that 
Jurkat rolling flux on P-selectin was lower than that of HL-60 cells (maximum of 75 rolling 
cells/mm2 for Jurkat cells, compared to 250 rolling cells/mm2 for HL-60 cells). Additionally, 
Jurkat cell rolling on immobilized P-selectin was limited to a smaller range of shear stresses 
compared to HL-60 cells. The differences in the trends between data from HL-60 cells and Jurkat 
cell flow assays are likely due to the fact that Jurkat cells express an improperly glycosylated 
form of PSGL-130 that results in a weaker receptor-ligand interaction that is correspondingly less 
stable when challenged with increasing levels of shear stress, compared to HL-60 cells that 
express fully functional PSGL-1. 
 Data from initial attachment assays of Jurkat cells on immobilized PSGL-1 suggest that 
there are optimal levels of shear stress that enable cells to more sensitively respond to differences 
in protein site density (Figure 3.7b). This is demonstrated by the fact that the dependence of 
rolling flux on site density at a shear stress of 0.62 dyn/cm2 was greater than at 0.47 or 0.93 
dyn/cm2. This demonstrates that there is a dynamic relationship between the combination of 
shear stress and site density on the observed cell rolling flux. 
 There are numerous other reports that utilize both leukocytes and leukocyte models (i.e., 
bioconjugated microspheres) in flow assays to better understand the biophysical phenomena 
66 
 
underlying leukocyte recruitment. Various selectin-ligand interactions have been studied using 
ligand-coated microspheres in flow assays.15,31 Selectin- or ligand-transfected cell lines,24 and 
various leukocyte subsets isolated from blood samples including T cells27,32 and neutrophils26,33 
have been assessed for their ability to roll on selectin-coated substrates. These in vitro 
approaches are complementary to in vivo studies and have the unique ability to provide a 
quantitative assessment of leukocyte recruitment (mediated by numerous different receptor-
ligand interactions) under well-defined experimental conditions. In this way, in vitro approaches 
have contributed to a clearer understanding of the complex physiological processes underlying 
the inflammatory response. 
 In addition to probing leukocyte interactions on substrates presenting one biomolecule at 
a time, I have demonstrated the potential for this gradient methodology platform to generate 
substrates presenting two biomolecules, and the subsequent application of these substrates to 
leukocyte flow assays (Figure 3.8).  Substrates were tailored to present a gradient of ICAM-1 
amidst a uniform background of P-selectin.  Leukocyte flow assays that probed the ability of HL-
60 cells to interact with the substrates through rolling and firm adhesion revealed that higher 
levels of ICAM-1 resulted in a greater percentage of adhered cells.  
 It is widely accepted that selectin-mediated rolling is a necessary first step to integrin-
mediated adhesion through interactions with intercellular adhesion molecules.26 Immobilized 
chemokines are often involved in this process, as they serve to activate expression of integrins on 
the cell surface,26,34 but some reports show that selectin-ligand interactions are sufficient for 
integrin activation.35  These findings are consistent with these reports, since cells failed to roll or 
adhere on substrates presenting ICAM-1 alone (data not shown), yet are able to roll and adhere 
upon substrates presenting both P-selectin and ICAM-1. Substrates that present multiple relevant 
ligands are valuable for their ability to probe the interplay between multiple biomolecular 
interactions that occur simultaneously in vivo.31b,36  
 The gradient generation approach described herein offers a means of streamlining the 
investigation of the interplay between ligand site density and applied shear stress, and their 
combined effects on rolling behavior by enabling the creation of high-information-content 
substrates that present many different underlying ligand conditions that can be assayed in a 
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single experiment.  Large-scale continuous gradients, such as those shown in Figures 3.3 and 3.5, 
have potential for applications in high-throughput multi-parameter analyses of cell-substrate 
interactions which would otherwise be more time- and labor-intensive due to the need to make 
multiple different substrates, each presenting different, uniform densities of the ligand(s) of 
interest. On the other hand, gradient arrays, such as those in Figure 3.8, can be tailored to present 
adhesive ligands in a manner that mimics an inflammatory site in a blood vessel wall, which can 
be on the order of 100s of µms in size,37 allowing the combined effects of biomolecule ligand 
density and feature size on the complete leukocyte recruitment process to be investigated. 
 This is the first demonstration of the generation and quantitative characterization of 
biomolecular surface gradients presenting a wide range of surface-immobilized protein site 
densities, and their subsequent application in a comparative study of rolling behavior of 
leukocyte cell lines.  I have assessed the combined effects of immobilized site density and shear 
stress on the resulting velocity and flux of rolling cells, demonstrating that this methodology is 
capable of generating gradient substrates for applications in rapid multi-parameter leukocyte 
flow investigations. Finally, although this manuscript is focused solely on leukocyte rolling 
assays, the general methodology of photochemical gradient generation will likely be of utility to 
a wide number of researchers interested in understanding biochemically complex cell-substrate 
interactions. 
3.3 Conclusion 
 Model substrates presenting biochemical cues immobilized in a controlled and well-
defined manner are of great interest for their applications in biointerface studies that elucidate the 
molecular basis of cell receptor-ligand interactions. This chapter presents a simple gradient 
generation approach that produces rationally controlled and quantifiable substrates, requiring 
only BP-modified glass substrates, protein solutions, and UV light. Immobilized proteins are 
shown to retain their function, as demonstrated by the ability of leukocytes to engage them in 
biologically relevant behaviors. This simple, direct and molecularly general approach to 
generating surface-immobilized biomolecular gradients produces substrates that are quantifiable 
and facilitate multi-parameter investigations of cell-substrate interactions.  
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 Gradient substrates have an advantage over homogeneous substrates for applications in 
leukocyte flow assays due to their ability to yield high-content data by probing numerous 
combinations of shear stress and immobilized site density in a single set of experiments. This 
approach is more efficient compared to generating numerous separate sets of substrates for each 
combination of ligands and parameters under investigation. Additionally, covalent 
immobilization of biomolecules eliminates the risk of protein desorption due to disrupted non-
covalent interactions. This methodology will be used to perform more comprehensive studies of 
selectin-mediated rolling of primary neutrophils and neutrophil models. Future work will also 
involve the generation of more complex substrates that simultaneously present multiple ligands 
in order to probe synergistic biomolecular interactions that control leukocyte rolling. These 
studies will be part of an effort to fully illuminate the cooperative effects of biomolecular 
interactions that facilitate leukocyte tethering, rolling, and adhesion to the endothelium during an 
inflammatory response. In addition to clear applications in leukocyte biology, this technique is 
well-suited to construct models for many cell-biomaterial interfaces that are defined by multiple 
modes of biomolecular interaction. This facile gradient generation methodology will enable 
biological studies that may lead to new insights into the biophysical phenomena and molecular 
mechanism underlying complex physiological processes such as leukocyte recruitment and the 
inflammatory response. 
3.4 Materials and Methods 
3.4.1 Preparation of BP-modified substrates 
All chemicals were purchased from Sigma-Aldrich, unless otherwise noted. Glass 
microscope slides were cleaned with piranha solution (3:1 v/v concentrated H2SO4:30% H2O2).38 
Slides were functionalized with 4-(triethoxysilyl)butyl aldehyde (Gelest) via vacuum deposition 
under reduced pressure for 2.5 hr at rt. Following silanization, slides were cured at 120 °C for 1 
hr, soaked in absolute ethanol for 30 min, and dried under a stream of nitrogen. Slides were then 
incubated in a solution of 20 mM 4-benzoyl benzylamine hydrochloride (Matrix Scientific) and 
200 mM NaCNBH3 in a 4:1 DMF:MeOH solution for 4 hr at rt. Remaining unreacted aldehyde 
groups were blocked by immersion in aldehyde blocking buffer (200 mM ethanolamine, 0.1 M 
Tris, pH 7) for 1 hr, followed by rinsing in DMF, methanol, and ethanol, and drying under a 
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stream of nitrogen. After each step, contact angle goniometry (Ramé-Hart) was used to confirm 
that the chemical functionalization was successful. The resulting BP-modified substrates were 
stored in a dessicator in the dark until use.  
3.4.2 Quantitative determination of immobilized protein density 
A standard method for quantifying immobilized protein site density on a surface involves 
incubating the substrate with a saturating concentration of radiolabeled antibody followed by 
analysis in a scintillation counter. A calibration curve of known standards is generated and used 
to convert the signal to a measure of site density (the number of antibodies bound per area), 
assuming 1:1 binding between the radiolabeled antibody and the antigen.14b,19 A similar method 
was employed to determine the site density of proteins (P-selectin or PSGL-1) covalently 
attached to BP-modified substrates, as previously described.9b Traditional radioimmunoassays 
are designed to determine the average site density of a substrate presenting a homogeneous layer 
of a single protein. Because the end goal was to determine site densities at various positions 
along immobilized protein gradient substrates, I needed a way to correlate data from 
fluorescence images with the site density data from the radioimmunoassays. To address this 
challenge, substrates presenting a homogeneous site density of protein were generated and split 
into two groups: one for fluorescence analysis and one for radioactivity analysis. The results 
from both studies were correlated to determine the relationship between fluorescence intensity 
(F.I.) and site density for each protein. In this way, gradient substrates were quantified by 
converting data from fluorescence analyses to site density using the standard curves from the 
fluorescence-radioactivity correlation studies.  
Solutions of P-selectin and PSGL-1 (R&D Systems) were freshly diluted from 
concentrated stocks (2 mg/mL) into PBS with Ca2+ and Mg2+ to a final concentration of 5 µg/mL. 
A BP-modified substrate was assembled into a rectangular parallel-plate flow chamber 
(GlycoTech) with a silicone gasket (127 µm thickness). The inlet and outlets tubes of the 
chamber were assembled to allow solution flow to be controlled by a syringe pump (Harvard 
Apparatus). Protein solutions were flowed through the chamber at 3 mL/min until filled (about 
200 µL required), then flow was stopped. A UV LED (365 nm, 17 mW/cm2, Clearstone 
Technologies) was employed to perform flood exposures of each substrate for various times (10, 
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30, 40, 60, 120, 180 sec) in the presence of each protein solution. Following protein 
photoimmobilization, the flow chamber was disassembled and substrates transferred to a solution 
of 1% BSA/0.5% Tween 20/PBS with Ca2+ and Mg2+ for 1 hr, and blocked in 1% BSA in PBS 
with Ca2+ and Mg2+ for an additional 1 hr. For each set of exposure conditions, six replicates 
were generated, three of which were subjected to fluorescence analysis, and three of which were 
analyzed for radioactivity and site density quantification.  
Substrate characterization via fluorescence required primary unlabeled mAbs (R&D 
Systems), and AlexaFluor647-labeled secondary mAbs (Invitrogen). For radioimmunoassays, an 
unlabeled secondary goat anti-mouse IgG/M polyclonal antibody (pAb, Amersham Biosciences), 
was iodinated with 125I (Perkin Elmer) using IODO-gen reagent (Pierce). [125I]-labeled pAb was 
purified using Bio-spin 6 columns (Bio-rad) to remove excess 125I, and characterized by thin 
layer chromatography to determine the specific activity and % free 125I (0.69 µCi/µg, 4.42% free 
125I).39 For fluorescence analysis, substrates were incubated with the appropriate primary mAb (1 
µg/mL) and AlexaFluor647-labeled secondary mAb (0.05 µg/mL) in 1% BSA/PBS overnight at 
rt. They were then rinsed in PBS and H2O, dried under a stream of nitrogen, and analyzed using 
a fluorescence slide scanner (GenePix 4000B, MDS Analytical Technologies). For radioactivity 
analysis and quantification, substrates were incubated with their respective primary mAbs (20 
µg/mL) in BSA/PBS at rt overnight, followed by incubation with [125I]-labeled secondary pAb 
(30 µg/mL) in BSA/PBS at room temperature for 30 min. Slides were then rinsed with PBS and 
water, dried under nitrogen, and cut into 1 x 2.5 cm pieces for analysis in a scintillation counter 
(LS 6500 Multi-Purpose Scintillation Counter, Beckman Coulter). Standards of [125I]-labeled 
secondary pAb were used to generate a standard curve, which was used to convert all 
radioactivity measurements to the number of molecules immobilized on the surface. This 
correlation assumes a 1:1 binding interaction between the primary antibody and the immobilized 
antigen, and also between the primary and secondary antibodies. Knowing the area of each 
substrate analyzed, the F.I. data was plotted as a function of site density (molecules/µm2) and 
linear regression analyses were performed to determine the linear fit for each set of data. The 
calibration curves, which were determined separately for P-selectin and PSGL-1, were used to 
convert all F.I. data from subsequent gradient substrates to units of site density (molecules/µm2). 
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3.4.3 Generation of surface-immobilized gradients 
For the creation of protein gradient substrates, an Ar ion laser (Coherent Innova 90-4, 
Laser Innovations, 351.1-363.8 nm) was employed for UV exposures and photoimmobilization. 
To enable large-area exposures with uniform illumination, the input Gaussian beam was 
converted to a flat-top output using a refractive beam shaper (π-Shaper, MT-Berlin), and 
expanded to a 1x1 cm2 exposure area with a beam-expanding telescope optic configuration. The 
profile of the input and output beams were characterized with a laser beam profiling camera 
(Ophir-Spiricon) to ensure that the beam was homogeneous across the exposure field. The laser 
power was adjusted to a final illumination intensity of 14 mW/cm2 at the substrate. 
In order to create a gradient of light exposure across the BP-modified substrate, a shutter 
was attached to a programmable translation stage (ThorLabs Opto DC Driver) and positioned 
between the light source and the substrate. Illumination and linear movement of the shutter were 
initiated simultaneously so that the substrate was exposed to a gradient in light exposure.  
The shutter was programmed to move 4.2 mm over a defined period (24-30 sec) while the 
substrate was exposed to the expanded and homogenized laser light. A BP-modified substrate 
was assembled in the flow chamber that was positioned beneath the shutter. After protein 
solutions were introduced into the chamber, UV exposure and shutter movement were initiated 
simultaneously. Following photoattachment, the flow chamber was immersed in a solution of 
0.5% Tween 20 in PBS with Ca2+ and Mg2+, the substrate was detached, and the same rinsing 
and blocking steps were performed as described above.  
Six replicate gradient substrates were generated for each protein; three were analyzed 
with fluorescence to determine site densities as detailed above, and the other three utilized in 
leukocyte flow assays. Conditions for incubation with fluorescently labeled binding partners and 
the fluorescence scanner settings were the same as described above. Fluorescence data were 
converted to units of site density in molecules/µm2, via the fluorescence-radioactivity correlation 
data. Substrates that were prepared for subsequent cell rolling studies were stored in BSA/PBS 
solution overnight.  
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3.4.4 Cell culture 
HL-60 promyelocytes were obtained from Prof. Fei Wang (University of Illinois) and 
Jurkat T lymphocytes were purchased from the American Type Culture Collection (ATCC). 
Cells were cultured in RPMI 1640 medium supplemented with penicillin (100 U/mL), 
streptomycin (100 µg/mL), and 10% heat-inactivated fetal bovine serum (SCS Cell Media 
Facility, UIUC). Cells were  passaged in order to maintain densities between 0.1 x 106 and 1.0 x 
106 cells/mL. 
3.4.5 Leukocyte flow assays 
Figure 3.1 shows the schematic of the setup that was employed for the leukocyte flow 
assays. Gradient substrates were assembled into the parallel-plate flow chamber while immersed 
in PBS with Ca2+ and Mg2+ to prevent drying out of the substrate which could result in protein 
denaturation. The tubing was connected to a syringe pump to control fluid flow and the chamber 
was positioned on top of an optical microscope (Zeiss 40C Invertiskop, Carl Zeiss Inc.). Cells 
were counted, pelleted for 5 min at 500 rcf, rinsed with HBSS with Ca2+ and Mg2+, and 
resuspended in 0.5% human serum albumin (HSA) in HBSS with Ca2+ and Mg2+ and 10 mM 
HEPES at pH 7.4, to a final concentration of 0.5 x 106 cells/mL. A digital video camera was used 
to record cells interacting with the substrate at various positions along the gradient while being 
subjected to defined amounts of wall shear stress. Shear stress was calculated using the equation 
τ = 6μQ/a2b, where μ is the apparent viscosity of the media, Q is the volumetric flow rate, and a 
and b are the height and width of the flow chamber, respectively. To calculate wall shear stress, 
the viscosity of buffer was assumed equal to water at room temperature (1.0 centipoise, 24 °C). 
Phase contrast microscopy was utilized to maximize contrast between interacting cells 
and the substrate, which was necessary to perform analyses with ImageJ software (National 
Institutes of Health). Using the MTrack2 plugin, the average velocity of rolling cells was 
determined (reported in µm/sec). To distinguish between interacting and non-interacting cells 
during the analysis, the critical velocity (vcrit) was determined for each flow rate.40 To determine 
vcrit, videos of non-interacting cells in shear flow near the wall of the flow chamber  were 
acquired and analyzed.40 Cells moving slower than the vcrit for at minimum of 1 sec (30 frames) 
were defined as rolling.  To determine rolling flux, cells were manually counted in the first 2 
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seconds of each video (reported as # rolling cells/mm2).  The field of view (FOV) for the 
microscope with a 20x objective was 0.174 mm2. 
In this study, initial attachment assays were performed to assess the ability of cells to 
initiate tethering and rolling while experiencing a defined level of wall shear stress. Cells were 
first introduced into the flow chamber at 3 mL/min (18.6 dyn/cm2) for 1 min; the flow rate was 
then dropped to achieve the desired shear stresses occurring from 10 to 500 µL/min. The pre-
determined shear stresses were 0.062, 0.16, 0.31, 0.47, 0.62, 0.93, 1.55 and 2.17 dyn/cm2. After 1 
min at each flow rate, videos (10 to 30 sec) were acquired at each position along the gradient (5 
to 7 positions per substrate). Between each shear stress that was investigated, the interacting cells 
were stripped from the surface by applying a high shear (3 mL/min, 18.6 dyn/cm2) and the 
process was repeated at the next flow rate. 
3.4.6 Statistical analysis 
For leukocyte flow assays, three replicates of each gradient substrate were generated for 
each of the two sets of assays, which were performed on different days. Data are reported as the 
average with error bars representing the standard error of the mean (SEM) for n=3 substrates, 
unless otherwise noted. To determine if a set of data showed correlation between dependent and 
independent variables (i.e., rolling flux and site density), correlation and linear regression 
analyses were performed. To determine if two data points were statistically different, one-sided 
two-sample t-tests were performed (Microsoft Excel), assuming population variances to be 
equal. Two-dimensional plots were generated using OriginPro8 (OriginLab) and 3D surface plots 
were created with SigmaPlot (Systat Software, Inc.). Statistical significance was set at a value of 
p<0.05. 
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Chapter 4 
 
Bromelain Cleaves P-selectin Glycoprotein Ligand-1 and Decreases 
Neutrophil Recruitment on Immobilized P-selectin In Vitro 
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4.1 Introduction  
Inflammation is a complex physiological process involving numerous receptor-ligand 
interactions between leukocytes and the endothelial lining of the blood vessel that ultimately lead 
to the trafficking of leukocyte subsets throughout the body.2 Numerous diseases are associated 
with dysregulated inflammation, including rheumatoid arthritis, asthma, psoriasis, thrombotic 
disorders, cancer, and autoimmune disease.3 
Bromelain is composed of several cysteine proteases isolated from pineapple extracts, 
and is currently marketed as an alternative or complementary medication for treating 
inflammation.4 Bromelain has been shown to alter multiple cell surface molecules involved in 
the adhesion and activation leukocytes,5 and while it has demonstrated anti-inflammatory, 
fibrinolytic, and anti-thrombotic effects in vivo and in vitro,6 the mechanisms by which 
bromelain attenuates leukocyte recruitment during inflammation remains poorly understood. 
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Amongst the enzymes present in bromelain extract is stem bromelain, which was used in this 
study and will be referred to as bromelain herein.  
Endothelial-expressed P-selectin and E-selectin play a central role during the initiation of 
an inflammatory response. When the endothelium receives distress signals from underlying 
tissue, P-selectin is the first biomolecule deployed as it is mobilized from intracellular storage 
pools to the luminal surface of the endothelium.7 The interaction between P-selectin and its 
primary leukocyte-expressed ligand, P-selectin glycoprotein ligand-1 (PSGL-1), supports 
neutrophil rolling along the surface of the blood vessel.8 E-selectin, which binds to PSGL-1 
 
Figure 4.1  Schematic of neutrophil flow assay setup. To determine the effects of bromelain 
treatment on neutrophil interactions with immobilized P-selectin or E-selectin under 
physiological shear stress, substrates presenting photoimmobilized P-selectin or E-selectin 
were prepared, characterized, and utilized in neutrophil flow assays with human neutrophils 
isolated from whole blood. 
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among other ligands,9 is also presented on the endothelium during the inflammatory response, 
but its expression is largely controlled by translation (i.e., it is not stored intracellularly),10 and its 
presentation temporally lags behind that of P-selectin in vivo. I felt it would be beneficial to 
independently probe bromelain’s effects on neutrophil interactions with substrates presenting 
each of these glycoproteins, so I applied a photochemical surface patterning strategy developed 
in our lab11 to generate substrates presenting P-selectin or E-selectin. I determined the site 
density of immobilized proteins using data from a previously reported radioimmunoassay,1 and 
interfaced the substrates with human neutrophils in flow assays to investigate the effect of 
bromelain treatment on the ability of human neutrophils to tether to and roll on P-selectin or E-
selectin (Figure 4.1). I chose to work with neutrophils amongst all the leukocyte subsets because 
they are among the first responders that rapidly accumulate at sites of inflammation.12 I used 
flow cytometry to analyze the expression of two ligands involved in leukocyte recruitment 
mediated by P-selectin and E-selectin: PSGL-1 and cutaneous lymphocyte antigen (CLA). The 
purpose of these studies was to determine the effects of bromelain treatment on the ability of 
neutrophils to interact with P-selectin and E-selectin under conditions of physiological shear 
stress and to shed light on the mechanisms underlying these effects. 
4.2 Results and Discussion 
Bromelain treatment of neutrophils nearly eliminates their ability to interact with P-
selectin presented on substrates in vitro, while E-selectin-mediated interactions are unaffected. 
The observations from neutrophil flow assays are complemented by a dose-dependence analysis 
of the effect of bromelain treatment on the expression of P-selectin and E-selectin ligands using 
flow cytometry, and suggest that bromelain’s anti-inflammatory effects may be attributed in part 
to its ability to cleave PSGL-1 and reduce the number of cells interacting with the inflamed 
endothelium. 
4.2.1 Bromelain treatment decreases tethering of human neutrophils to immobilized P-selectin, 
has no effect on neutrophil interactions with immobilized E-selectin 
 Using a method I previously developed for the photochemical immobilization of 
biomolecules on planar substrates,11 I generated and characterized substrates presenting “high”  
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and “low” levels of P-selectin or E-selectin on BP-modified substrates (Figure 4.2). Substrates 
were characterized with fluorescence imaging and average fluorescence intensity values (Table 
4.1) were converted into site densities using fluorescence-radioactivity correlation data that was 
previously reported data for P-selectin1 and determined for E-selectin for this study (Figure 4.3). 
  
The data from the neutrophil flow assay experiments are presented in Figure 4.4. In the 
first set of neutrophil flow assays with P-selectin-presenting substrates, human neutrophils were 
isolated (>90% pure, >95% viable) and flowed at a constant shear stress (1.28 dyn/cm2) over  
 
Figure 4.2  Fluorescence images and linescans from substrates presenting high and low levels 
of photoimmobilized (a) P-selectin or (b) E-selectin. Scale bar = 1 mm. Sites densities for P-
selectin substrates were determined using data from a previously reported 
radioimmunoassay.1 Data from a radioimmunoassay for E-selectin (see SI) were used to 
determine site densities of E-selectin substrates.  
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substrates presenting immobilized P-selectin at two different site densities (700 and 
250 molecules/μm2). I observed that the number of interacting cells is significantly lessened 
when neutrophils are treated with 50 μg mL-1 bromelain, compared to the RPMI-treated control 
sample (p<0.05). Incubation of control cells with saturating levels of anti-PSGL-1 clone KPL-1 
(30 μg mL-1), which recognizes an epitope encompassing three sulfated tyrosines in PSGL-1’s 
active site (Figure 4.5), also resulted in a decrease in the number of interacting cells, suggesting 
that the altered behavior following bromelain treatment is the result of bromelain cleaving off 
this portion of the PSGL-1’s active site, which is required for interactions with P-selectin but not 
E-selectin.13  
In a separate set of experiments involving E-selectin-presenting substrates, human 
neutrophils were flowed at 1.28 dyn/cm2 over substrates presenting two different site densities of 
immobilized E-selectin (750 and 400 molecules/μm2). In contrast to flow assay experiments on  
 
Table 4.1  Average fluorescence intensity and site density determination for P-selectin and E-
selectin substrates. Substrates were incubated with fluorescently labeled antibodies, and 
fluorescence intensity units were converted to site density (molecules/μm2) using a previous 
reported calibration curve (see Figure 3.2) for P-selectin, and newly reported data for E-
selectin (Figure 4.3).  
 
P-selectin
Substrate
F.I., low-
3 sec
Molecules
/μm2
F.I., High-
30 sec
Molecules
/μm2
P1 679.00 295.36 2978.00 1073.10
P2 475.00 226.34 1316.00 510.85
P3 506.00 236.83 1187.00 467.21
P4 434.00 212.47 1164.00 459.43
P5 268.00 156.32 1131.00 448.26
Average 472.40 225.46 1555.20 591.77
stdev 147.54 49.91 798.46 270.11
SEM 65.98227 22.32 357.08 120.80
Approximations:
Low P-selectin: 250 molecules/μm2
High P-selectin: 600 molecules/μm2
E-selectin
slide
F.I., Low-
6 sec
Molecules
/μm2
F.I., High-
60 sec
Molecules
/μm2
E1 618.70 371.27 1088.00 449.90
E2 812.00 403.66 6805.00 1407.78
E3 541.00 358.25 801.00 401.82
Average 657.23 377.73 2898.00 753.17
stdev 139.55 23.38 2765.15 567.42
SEM 62.40811 13.50 1236.61 327.60
Approximations:
Low E-selectin: 400 molecules/μm2
High E-selectin: 750 molecules/μm2
For P-selectin:
Site density = 2.96(F.I.)-194.07, R2 = 0.92
For E-selectin:
Site density = 5.97(F.I.)-1597.20, R2 = 0.91
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P-selectin-presenting substrates, bromelain treatment had no significant effect on the ability of 
neutrophils to tether to immobilized E-selectin. I did observe that a greater number of cells 
interacted with the region of the substrate presenting E-selectin at a site density of 
750 molecules/μm2 compared to 400 molecules/μm2 (p<0.05). These findings suggest that 
bromelain is not able to cleave E-selectin ligands to reduce or eliminate E-selectin-mediated 
interactions. Incubation of neutrophils with saturating levels of HECA-452 (30 μg mL-1), which 
recognizes a glycan moiety known as cutaneous lymphocyte antigen (CLA) that is present on 
several E-selectin ligands, did not significantly decrease neutrophil interactions on immobilized 
 
Figure 4.3  The relationship between fluorescence intensity and site density was determined 
for photoimmobilized E-selectin on BP-modified substrates. Substrates were generated in 
triplicate via flood UV exposures in the presence of protein solution, resulting in 
homogeneous substrates presenting a wide range protein site density levels. Fluorescence 
measurements were acquired after incubating substrates with fluorescently labeled antibodies. 
For site density determination, substrates were incubated with saturating concentrations of 
primary monoclonal antibody (mAb) and [125I]-labeled secondary polyclonal antibody (pAb). 
Control substrates were used to account for non-specific mAb and pAb binding. Data is 
plotted as the average (± 95% C.I.) for n=3 substrates.  
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E-selectin. These findings suggesting that E-selectin-mediated neutrophil rolling occurs via 
interactions with ligands in addition to those presenting the CLA carbohydrate epitope. 
  As a control experiment, I tested whether neutrophils would interact with BP-modified 
substrates blocked with HSA without P-selectin or E-selectin. Neutrophils did not interact with 
 
Figure 4.4  Data from neutrophil flow assays reveals that treatment of neutrophils with 50 μg 
mL-1 bromelain  (a) decreases the formation of new tethers on immobilized P-selectin 
substrates relative to RPMI-treated neutrophils (p<0.05), but (b) has no effect on neutrophil 
interactions with immobilized E-selectin. Treatment of neutrophils with saturating 
concentrations of anti-PSGL-1 (clone KPL-1) decreased neutrophil tethering of neutrophils to 
immobilized P-selectin substrates, suggesting that the mechanism by which bromelain 
decreases tethering to P-selectin substrates is by cleaving a portion of the PSGL-1 active site 
required for P-selecting binding.  Neutrophils failed to interact with HSA-blocked control 
substrates. Scale bar: 80 μm. 
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HSA-blocked substrates (data not shown), which suggests that the observed cell-substrate 
interactions were the result of specific receptor-ligand interactions. 
 
Results from the described neutrophil flow assays suggest that bromelain cleaves PSGL-1 
in a manner that abolishes its ability to recognize P-selectin. However, bromelain appears to have 
no effect on the ability of neutrophils to interact with immobilized E-selectin, suggesting that E-
selectin ligands, or at least the regions of E-selectin’s ligands that are required for E-selectin 
binding, are not cleaved by bromelain.  
4.2.2 Bromelain cleaves PSGL-1 near N-terminal active site and causes a dose-dependent 
decrease in PSGL-1 expression on human neutrophils.  
In order to determine what is going on at the molecular level when neutrophils are treated 
with bromelain, I set out to perform flow cytometry analysis of human neutrophils to determine 
how expression levels of ligands for P-selectin and E-selectin, namely PSGL-1 and CLA, are 
affected by bromelain treatment (Figure 4.6). I obtained three antibodies that recognize well-
characterized epitopes that are present on PSGL-1 and CLA. Then I treated human neutrophils 
 
 
Figure 4.5  Two portions of the N-terminal active site of PSGL-1 are responsible for P-
selectin binding—sulfated tyrosine residues (Tyr46, Tyr48 and Tyr51) and a glycosylated 
threonine residue (Thr57).  
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with various doses of bromelain (from 10 to 100 μg mL-1) or RPMI and used flow cytometry 
analysis to determine how bromelain treatment affects surface expression of PSGL-1 and CLA.  
To analyze PSGL-1 expression, I used monoclonal antibody (mAb) clones CHO131 and 
KPL-1. Clone CHO131 recognizes the sialyl-Lewisx–bearing core 2 O-glycan structures 
 
Figure 4.6  Bromelain treatment decreases expression levels of surface-expressed PSGL-1 
and CLA in a dose-dependent manner. (a,b) To determine expression levels of PSGL-1, the 
primary ligand for P-selectin, following bromelain treatment, two anti-PSGL-1 antibodies that 
recognize distinct regions within the protein’s active site were used. The epitope for clone 
KPL-1 (red) is closer to the N-terminal tip of the extracellular portion of PSGL-1 than the 
epitope for clone CHO131 (blue). The data suggest that the primary site of bromelain 
cleavage is between the two epitopes within PSGL-1’s active site. (c) The effect of bromelain 
treatment on expression of a carbohydrate epitope CLA, which is required for recognition of 
some ligands by E-selectin, was assessed with anti-CLA, clone HECA-452 (green).  
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presented at PSGL-1’s active site. This glycan structure is one of the two regions known to be 
required for high-affinity P-selectin binding.14 The epitope for clone KPL-1 has been mapped to 
a site that includes the tyrosine sulfation motifs that comprise the second of the two regions 
known to be essential for interaction with P-selectin, and the antibody has been reported to 
completely block interactions with P-selectin without affecting leukocyte recognition of E-
selectin.15  
The data suggest that bromelain treatment reduces PSGL-1 expression on human 
neutrophils by directly cleaving PSGL-1 at a site between the epitopes for clones KPL-1 and 
CHO131 (Figure 4.6). Flow cytometry analysis with clone KPL-1 reveals that the level of the 
PSGL-1 tyrosine sulfation motif, which is required for recognition by P-selectin but not E-
selectin,13 sharply drops to about 20% as the bromelain dose increases from 0 to 100 μg mL-1. 
Flow cytometry analysis with clone CHO131, however, shows that PSGL-1 expression levels 
either increase or remain roughly the same at all concentrations of bromelain tested (Figure 4.6).  
 
These data suggest that bromelain may be causing two things to happen to neutrophils 
simultaneously: Bromelain may trigger an increase in PSGL-1 surface expression through an 
outside-in mechanism at low doses, while at the same time cleaving PSGL-1 on the surface at a 
position within the N-terminal active site, yet upstream of the sialyl-Lewisx–bearing core 2 O-
glycan structures. Treatment of human neutrophils with deactivated bromelain had no significant 
 
Figure 4.7  Flow cytometry analysis of PSGL-1 and CLA expression on neutrophils treated 
with RPMI or deactivated bromelain reveals that deactivated bromelain has no significant 
effect on PSGL-1 or CLA expression levels. 
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effect on neutrophil expression of PSGL-1 (Figure 4.7), suggesting that enzyme activity is 
required to induce the changes in surface expression of PSGL-1 that I observed following 
treatment with active bromelain. 
PSGL-1 is P-selectin’s primary ligand in vivo and is also one of several known ligands 
for E-selectin.9 Previous studies involving mouse models revealed that when PSGL-1 is knocked 
out or blocked, P-selectin-mediated leukocyte rolling is completely eliminated, while E-selectin-
mediated rolling still occurs.16 Since P-selectin is the first selectin expressed on the endothelial 
lining of the blood vessel immediately in response to proinflammatory signals, interactions 
between P-selectin and PSGL-1 are among the first receptor-ligand interactions that initiate 
tethering and rolling of leukocytes during an inflammatory response.7 It is interesting to note that 
at the doses used in this study, bromelain cleaves off one of the two motifs in PSGL-1’s active 
site that are required for P-selectin recognition, while leaving the region required for E-selectin 
recognition intact.  
I also determined the effects of bromelain treatment on expression levels of CLA, a 
carbohydrate epitope shared by sialyl-Lewisx and sialyl-Lewisa structures that has been found to 
be present on PSGL-1 and other E-selectin ligands,17 and plays a role in leukocyte tethering and 
rolling mediated by E-selectin.18 To characterize CLA expression on neutrophils, I used clone 
HECA-452, a widely used monoclonal antibody for CLA detection. 
 The data reveal that the average CLA expression declines in a nearly linear fashion to 
about 80% as the dose of bromelain increases from 0 to 100 μg mL-1. Similar to flow cytometry 
analysis of PSGL-1 expression, treatment of human neutrophils with deactivated bromelain 
caused minimal changes in the surface expression of CLA (Figure 4.7). 
It is interesting to note that although both PSGL-1 active site epitopes are required for P-
selectin recognition, only the Thr O-glycan moiety recognized by mAb CHO131 is required for 
E-selectin recognition.13 This could explain why although bromelain cleaves off the sulfated 
tyrosine residues that are required for P-selectin binding and significantly attenuates neutrophil 
interactions with immobilized P-selectin under shear stress, there is not a significant change in 
neutrophil interactions with immobilized E-selectin following bromelain treatment.  
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While other research labs have investigated the effects of bromelain treatment on 
neutrophil migration in response to chemokines,5,19 this report represents the first to reveal that 
bromelain cleaves PSGL-1, P-selectin’s primary ligand that is involved in the onset of selectin-
mediated leukocyte rolling during inflammation, and results in an attenuation of rneutrophil 
recruitment on immobilized P-selectin in vitro. These findings suggest that a potential 
mechanism by which bromelain exerts its anti-inflammatory effects in vivo is by cleaving PSGL-
1, one of the key ligands responsible for the initial tethering and rolling of leukocytes to P-
selectin on the inflamed endothelium. Additional studies will be needed to investigate if 
bromelain exerts similar effects on neutrophils in vivo. Further investigations into the molecular 
details of bromelain’s effects on neutrophil-selectin interactions may help shed additional light 
on how bromelain exerts its anti-inflammatory effects in vivo and lay the foundation for the 
development of more effective anti-inflammatory treatments. 
4.3 Materials and Methods  
4.3.1 Preparation and characterization of substrates presenting P-selectin or E-selectin  
Substrates presenting immobilized P-selectin or E-selectin were prepared using a 
previously reported photochemical immobilization method I developed.11 All chemicals were 
purchased from Sigma-Aldrich, unless otherwise noted.  
Briefly, glass microscope slides were cleaned with Piranha solution (3:1 v/v concentrated 
H2SO4/30% H2O2),20 reacted with 4-(triethoxysilyl)butyl aldehyde (Gelest) under reduced 
pressure for 2.5 hr, cured at 120 °C for 1 hr, then soaked in 200 proof EtOH for 30 min and dried 
under a stream of nitrogen. Substrates were then incubated with 20 mM 4-benzoyl benzylamine 
hydrochloride (Matrix Scientific) and 200 mM NaCNBH3 in PBS (pH 7.4) for 4 hr, followed by 
immersion in aldehyde-blocking buffer (200 mM ethanolamine, 0.1 M Tris, pH 7) for 1 hr. The 
resulting BP-modified slides were rinsed with water, MeOH, EtOH, dried under a stream of 
nitrogen, and stored in a dessicator until use. P-selectin and E-selectin (R&D Systems) were 
freshly diluted from concentrated stocks into PBS with Ca2+ and Mg2+ (Sigma) to a final 
concentration of 2.5 µg mL-1. BP-modified substrates were assembled into a rectangular parallel-
plate flow chamber (GlycoTech) with a silicone gasket (127 µm thickness). Protein solutions 
were flowed through the chamber at 3 mL/min until filled, then flow was ceased. Protein 
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photoimmobilization was enabled through the use of an Ar ion laser (Coherent Innova 90-4, 
Laser Innovations, 351.1-363.8 nm), whose Gaussian beam profile was converted to a flat-top 
profile using a π-Shaper (MT-Berlin), and expanded to a 1 cm2 area using beam-expanding 
optics (ThorLabs). The final output power was adjusted to 14 mW/cm2 for protein 
photoimmobilization. Exposure conditions were optimized to generate binary substrates 
presenting a 1 cm2 area of high protein site density (650-750 molecules/μm2) and a 1 cm2 area of 
low protein site density (250-400 molecules/μm2) on each substrate. The two separate areas of 
each substrate were subjected to UV exposure for 3 or 30 seconds (for P-selectin) and for 6 or 
60 seconds (for E-selectin), and a total of 7 or 8 replicates substrates were generated with each 
protein. Substrates for flow assay experiments were stored in 0.5% HSA in HBSS with Ca2+ and 
Mg2+ and 10 mM HEPES (pH 7.4, HBSS/HEPES) until use, while the remaining replicate 
substrates were characterized with fluorescence and converted to site density.  
Data for quantitation of P-selectin substrates has been previously reported,1 while data for 
E-selectin quantitation was obtained for this study (Figure 4.3). I generated substrates presenting 
varying levels of immobilized E-selectin in a defined area on BP-modified substrates, and split 
the substrates into two groups: one group for fluorescence analysis and the other for radioactivity 
analysis. The data from both studies were correlated to determine the relationship between 
fluorescence intensity (F.I.) and site density for each protein. Using the equation from the linear 
regression for the resulting calibration curves, binary substrates were quantified by converting 
data from fluorescence analyses to site density. The procedure for correlating fluorescence units 
to site density has been previously reported.1  Briefly, a solution of E-selectin (R&D Systems) 
was freshly diluted from a concentrated stock into PBS with Ca2+ and Mg2+ to a final 
concentration of 5 µg/mL. A BP-modified substrate was assembled with a silicone gasket into a 
rectangular parallel-plate flow chamber. Protein solutions were flowed through the chamber at 3 
mL/min until filled (about 200 µL required), then flow was stopped. A UV LED (365 nm, 
17 mW/cm2, Clearstone Technologies) was employed to perform flood exposures of each 
substrate for various times (0, 15, 30, 60, or 120 sec) in the presence of E-selectin solution. 
Following protein photoimmobilization, the flow chamber was disassembled and substrates 
transferred to a solution of 1% BSA/0.5% Tween 20/PBS with Ca2+ and Mg2+ for 1 hr, and 
blocked in 1% BSA in PBS with Ca2+ and Mg2+ for an additional 1 hr. For each set of exposure 
conditions, six replicates were generated, three of which were subjected to fluorescence analysis, 
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and three of which were analyzed for radioactivity and site density quantification. One set of 
substrates was incubated with a fluorescently labeled binding partner (1 μg/mL unlabeled anti-E-
selectin from R&D Systems  and 0.5 μg/mL AlexaFluor647-labeled secondary mAb from 
Invitrogen), and imaged on a fluorescence microarray scanner (GenePix 4000B, MDS Analytical 
Technologies). The other set was incubated with a saturating concentration (20 μg/mL) unlabeled 
anti-E-selectin from R&D Systems at rt overnight, followed by incubation with [125I]-labeled 
secondary goat anti-mouse IgG/IgM polyclonal antibody (pAb, Amersham Biosciences, 
30 µg/mL, 0.69 µCi/µg, 4.42% free 125I) in BSA/PBS at rt for 30 min, followed by analysis with 
a scintillation counter (LS 6500 Multi-Purpose Scintillation Counter, Beckman). Under the 
conditions used, I observed a linear relationship between the fluorescence  intensity (F.I.) and 
corresponding radioactivity signal (converted from cpm to site density using a standard curve of 
known amounts of [125I]-labeled goat anti-mouse IgG/IgM pAb) was linear for each set of 
immobilized protein substrates. The reported site densities are an estimate based on the ability of 
antibodies to detect the proteins. For simplicity, I assume a 1:1 binding relationship between the 
[125I]-labeled secondary polyclonal antibody (pAb) and primary monoclonal antibody (mAb), 
which likely results in an overestimate of protein loading, since each primary mAb might be 
recognized by multiple secondary [125I]-labeled pAbs. I also assume a 1:1 binding relationship 
between the primary mAb and the immobilized surface proteins, although each primary mAb has 
two antigen binding sites. Similar methods and assumptions have been previously made for 
substrates used in quantitative selectin-ligand assays.21 
4.3.2 Neutrophil flow assays on P-selectin and E-selectin  
Substrates presenting P-selectin or E-selectin were utilized in flow assays with human 
neutrophils, shown schematically in Figure 1. While immersed in HBSS/HEPES, substrates were 
assembled into a rectangular parallel-plate flow chamber with a silicone gasket (254 μm 
thickness). Solution flow through the chamber was controlled by a syringe pump (Harvard 
Apparatus). The flow chamber assembly was positioned on top of an optical microscope (Zeiss 
40C Invertiskop, Carl Zeiss, Inc.).  
Human neutrophils were isolated from whole blood by density centrifugation using 
Ficoll-Paque, followed by red blood cell lysis and negative selection with magnetic particles 
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from the EasySep Human Neutrophil Enrichment Kit, following the manufacturer’s protocols 
(STEMCELL Technologies). Blood was obtained from healthy adults, who were recruited as 
blood donors and gave informed consent for participation. All protocols for human subjects 
research were approved by the Institutional Review Board at the University of Illinois at Urbana-
Champaign (IRB Protocol Number: 11117).  
To assess the purity of isolated neutrophils, cells were blocked with 3% HSA and 
incubated with two antibodies against neutrophil cell surface markers: PE-labeled anti-CD16 and 
FITC-labeled anti-CD66b monoclonal antibodies (STEMCELL Technologies). Neutrophil purity 
 
Figure 4.8  Flow cytometry analysis of human neutrophils for neutrophil markers (a) CD66b 
and (b) CD16 revealed >90% neutrophil purity in all cell samples isolated for neutrophil flow 
assay experiments (representative data shown). Neutrophils were isolated using traditional 
Ficoll-Paque density centrifugation followed by magnetic bead separation. Control sample 
(black) were incubated with fluorescently labeled isotype control antibodies. 
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was analyzed with flow cytometry (Figure 4.8) and cell viability was determined with standard 
trypan blue staining and counting. The remaining neutrophils were split into three separate tubes 
and pelleted for 5 min at 500 rcf. One sample was resuspended in a solution of 50 μg mL-1 
bromelain in RPMI, and the other two samples were resuspended in RPMI alone. All samples 
were incubated for 30 min at 37 °C, at which point samples were washed with 
HSA/HBSS/HEPES and cells were pelleted for 5 min at 500 rcf. One of the RPMI-treated 
neutrophil samples was resuspended in 30 μg mL-1 anti-PSGL-1 (clone KPL-1, for experiments 
with P-selectin substrates) or anti-CLA (clone HECA-452, for experiments with E-selectin 
substrates) and incubated at rt for 30-60 min before being diluted to 0.5 E 6 cells/mL for flow 
assay experiments. The remaining two samples’ cell pellets were immediately resuspended in 
HBSS/HEPES containing 0.5% HSA to a final concentration of 0.5 E 6 cells/mL. All samples 
were used in flow assay experiments within 2 hours of bromelain or RPMI treatment. 
Neutrophils were introduced into the chamber at a high flow rate (3 mL/min, 9.3 dyn/cm2) 
for 1 min, then the flow rate was then dropped to 400 μL/min (1.28 dyn/cm2). After 1 min, 20-
30 sec videos were acquired at 4-5 positions in each area of the substrate (high site density and 
low site density).  For each set of flow assay experiments (involving P-selectin or E-selectin 
substrates), neutrophils from three donors were used to perform independent experiments on 
three replicate substrates. For each substrate, the number of new tethers formed per unit area and 
time was determined by counting the number of cells that interacted with the surface. Cells that 
were already rolling or adhered upon the surface were not included in the analysis. HSA-blocked 
BP-modified substrates were used as control substrates to verify that the observed interactions 
were due to neutrophil interactions with immobilized P-selectin or E-selectin. Data from 
neutrophil flow assays are reported as the average (±SEM) for n=3 substrates. 
4.3.3 Flow cytometry analysis of bromelain’s effect on the expression of cell surface molecules 
Human neutrophils were isolated from whole blood as described above. Neutrophils were 
prepared for analysis of expression of PSGL-1 and CLA following treatment with 0, 10, 25, 50, 
or 100 μg mL-1 bromelain in RPMI cell cultre medium for 30 min at 37 °C. In some experiments, 
an additional aliquot of cells were treated with deactivated bromelain, which was prepared by 
reacting bromelain with dithiothreitol and iodoacetamide and removing excess reagents with a 
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Zeba spin filter column (Pierce), followed treatment with a proteinase cocktail inhibitor solution 
containing the cysteine-protease deactivating molecule E-64, according to manufacturer’s 
protocols. Following incubation with bromelain or RPMI, cell samples were washed with 
HSA/HBSS/HEPES and cells were pelleted for 5 min at 500 rcf. After aspirating the supernatant, 
neutrophils were blocked for 15 min with 3% HSA in HBSS/HEPES, followed by incubation for 
30 min with primary monoclonal antibodies and fluorescently labeled secondary antibodies at 
final concentrations of 10 and 20 μg mL-1, respectively, in HSA/HBSS/HEPES.  For detection of 
cell-surface PSGL-1, I used mouse anti-human PSGL-1 clone KPL-1 (Millipore), and mouse 
anti-human PSGL-1 clone CHO131 (R&D Systems). For detection of CLA, the HECA-452 
clone (BioLegend) was used. For all samples, I used a fluorescently labeled secondary antibody: 
phycoerythrin (PE)-conjugated goat anti-mouse IgG (Invitrogen). Cell samples were stained for 
only one antigen at a time. Control samples were incubated with the PE-labeled secondary 
antibody only. Solutions composed of primary and secondary antibodies were preincubated for at 
least 1 hr prior to incubation with cells. Cells were analyzed with BD FACSCanto II cytometer 
(BD Biosciences).  
Flow cytometry data was processed using FCS Express (BD Biosciences). Fluorescence data 
from neutrophil populations were plotted in histogram form, and the average fluorescence 
intensity from each sample was plotted as the percentage of the antigen expression from the 
RPMI-treated sample as a function of bromelain concentration. Data are reported as the average 
(±SEM) for n=3-6 donors. 
4.3.4 Statistical Analysis 
Student’s unpaired t test was used to determine p values and compare differences 
between groups. Statistical significance was set at a value of p<0.05. 
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Chapter 5 
 
Future Outlook 
 
In this work, I have presented a summary of my progress toward the development of a 
direct, photochemical method for the generation of biomolecular interfaces for applications in 
leukocyte biology. I have described my work toward applying the developed methodology to the 
investigation of selectin-mediated leukocyte rolling and studies on the mode of action of a 
natural anti-inflammatory agent, bromelain. 
Future work will include investigations into the molecular mechanism underlying the 
reduction in selectin-mediated rolling in vitro caused by bromelain treatment. The investigation 
will also be extended to consider the effect of bromelain treatment on the subsequent stages of 
leukocyte recruitment, such as leukocyte adhesion and migration in response to both 
immobilized and soluble biochemical cues.  
Both biochemical and bioanalytical tools will be used in addition to, or in conjunction 
with, the biointerface generation methodology, to tease out the molecular details behind 
bromelain’s anti-inflammatory properties. Future work will also involve substrates that 
simultaneously present multiple ligands to cells, both on the surface and in solution, in order to 
probe synergistic biomolecular interactions that control leukocyte rolling. Finally, future work 
will include studies on bromelain’s effects on leukocyte interactions with cytokine-stimulated 
endothelial cell monolayers, which better mimic the physiological environment of the inflamed 
blood vessel. These studies will serve to fully illuminate the cooperative effects of the 
biomolecular interactions that facilitate leukocyte tethering, rolling, and adhesion to the 
endothelium during an inflammatory response, and the molecular details underlying the anti-
inflammatory properties of bromelain.  
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5.1 Bioanalytical characterization: What is the molecular mechanism underlying 
bromelain’s cleavage of neutrophil-expressed PSGL-1? 
 In the results presented in Chapter 4, I observed that bromelain treatment of neutrophils 
results in a decrease in neutrophil tethering and rolling on substrates presenting immobilized P-
selectin, but has no effect on neutriphil interactions with substrates presenting immobilized E-
selectin (Fig. 4.7). Flow cytometry analysis of P-selectin expression on neutrophils with 
antibodies recognizing two epitopes within P-selectin’s active site revealed that bromelain 
treatment results in a decrease in the presence of one the two epitopes, leaving the other epitope 
largely intact (Fig. 4.2). In combination, these data support the hypothesis that bromelain cleaves 
neutrophil-expressed PSGL-1 in vitro at a site within its N-terminal active site. 
 To further probe this hypothesis, future work will include performing molecular analyses 
to determine exactly where bromelain is cleaving PSGL-1. This will include three different 
experiments involving (a) a synthetic peptide representing PSGL-1’s active site, (b) 
recombinantly expressed PSGL-1, and (c) cell surface-bound PSGL-1 expressed on human 
neutrophils. 
5.1.1 Studies involving a synthetic peptide representing PSGL-1’s active site 
A 19-amino acid synthetic peptide representing PSGL-1’s active site (Figure 5.1) will be 
obtained. The peptide will include the sulfated tyrosines (Tyr46, Tyr48, Tyr51) located near the 
N-terminus, which encompasses the region that appears to be cleaved off following bromelain 
treatment. The peptide extends several amino acids past the threonine residue, which in the 
native protein presents the sulfation moiety that is recognized my mAb CHO131 that does not 
appear to be cleaved off with bromelain treatment (Figure 4.2). Although the synthetic peptide 
will not include the glycosylation moiety at Thr57 and may not have the same tertiary structure 
as native PSGL-1, the results from these studies will show whether bromelain is able to cleave 
PSGL-1 at some (or many) position(s) between these two components of the active site. The 
peptide (1 mg/mL) will be incubated with bromelain (100 μg/mL) in ammonium acetate buffer 
(pH 7), and remove and quench aliquots at pre-determined time points with 0.5% trifluoroacetic 
acid (TFA). Ammonium acetate buffer will be used because of its compatibility with mass 
spectrometry analysis due to its low volatility.2 Samples will be prepared for analysis with 
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matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS, 
or MALDI). MALDI data from the analysis of the untreated peptide will be compared to the 
bromelain-treated peptide and see if a specific cleavage site is observed. I predict the results of 
these studies will reveal that bromelain cleaves PSGL-1 within its active site. 
 
The limitations of bioanalytical studies with a synthetic peptide include that the peptide 
may not have the tertiary structure that it has when it is presented in its native context, and thus 
bromelain may not act upon the PSGL-1 active site peptide in the same way it is able to act upon 
native PSGL-1 expressed on the surface of neutrophils. Furthermore, while peptide studies can 
reveal that bromelain is able to cleave within the active site, these studies will not be able to 
determine that bromelain is not cleaving PSGL-1 elsewhere. Thus, peptide studies will need to 
be supported by other studies involving native PSGL-1.  
5.1.2 Studies involving recombinant human PSGL-1 
Following analyses of bromelain digestions of the peptide active site, a recombinantly 
expressed human PSGL-1 (R&D Systems) will be obtained and incubated with bromelain to see 
 
Figure 5.1  The 19-amino acid peptide shown above represents PSGL-1’s N-terminal active 
site and will be used in bromelain digestion studies to see if bromelain is capable of cleaving 
off the epitope recognized by monoclonal antibody clone KPL-1 (shown in blue), which is 
required for P-selectin recognition. 
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if the data reveals the expected peptides are cleaved from the N-terminal active site. The active 
site of the recombinant form of PSGL-1 has all the native modifications, including the tyrosine 
sulfations and the gycosylation moiety at Thr57, so it should be a more accurate model of what 
bromelain “sees” on the neutrophil surface when it cleaves PSGL-1, compared to the synthetic 
peptide. Digestion studies will be performed, samples will be prepared for analysis, and finally 
MALDI-TOF-MS analyses will be carried out to determine which peptide fragments were 
cleaved off during bromelain treatment. Tandem mass spectrometry (MS/MS) will be used to 
confirm the amino acid sequences of expected fragments observed in the initial MALDI analysis. 
However, even these studies with recombinant PSGL-1 may be limited by the fact that 
the soluble protein may interact differently with bromelain than the cell surface-bound protein. 
PSGL-1 is expressed as a homodimer on the surface of leukocytes,3 whereas the recombinant 
form exists as a monomer that is expressed attached to a mouse Fc chimera. In preliminary 
studies, I observed bromelain cleave recombinantly expressed PSGL-1 in more places than 
expected. For this reason, it is apparent that to concretely determine bromelain’s effects on 
PSGL-1 at the molecular level, one will need to perform these bromelain digestion experiments 
with cell-surface-bound PSGL-1. 
5.1.3 Studies involving neutrophil-expressed PSGL-1 
To concretely confirm, at a molecular level, that bromelain is acting on PSGL-1 by 
cleaving the N-terminal portion of the active site as is suggested by results presented in Chapter 
4, neutrophils will be treated with bromelain and the supernatant will be analyzed using mass 
spectrometry. 
Mass spectrometry analysis of cell supernatant following bromelain treatment will be 
much more involved than studies on enzymatic digestion of a recombinant protein or peptide in 
solution. Bromelain is able to cleave synthetic peptides most efficiently with Arg-Arg sites and is 
able to preferentially cleave glycyl and alanyl bonds,4 but unlike certain proteolytic enzymes that 
require specific consensus sequences to enable protein cleavage, bromelain does not appear to 
have a consensus sequence for cleavage. This makes it difficult to predit protein sensitivity based 
on the primary amino acid sequence alone.5 Previous studies have shown that bromelain alters 
the expression levels of several cell-surface-bound proteins that are involved in cell adhesion and 
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migration.5a,6 It is not unreasonable, therefore, to suspect that bromelain is able to cleave 
hundreds of cell surface bound proteins, which could result in the supernatant containing 
hundreds or thousands of different peptide fragments, which will make identifying the PSGL-1 
fragments like finding a needle in a haystack. 
Because the sample is a complex biological sample, high-performance liquid 
chromatography (HPLC) will be needed to help separate out the various components present in 
the sample. An LC/MS instrument that couples the separating power of HPLC with an 
electrospray ionization (ESI) source will be used to allow each peak that elutes off the column to 
be analyzed by mass spectrometry. 
 While LC/MS is a robust technique and is broadly used for analysis of biological 
samples,7 considerable user time will be spent optimizing the experimental conditions, the 
sample preparation procedure, and the LC/MS method parameters. 
 At the experimental level, one will need to optimize the bromelain concentration and 
digestion time such that enzymatic cleavage of PSGL-1 occurs without over-digesting the 
peptide of interest to the point where it is no longer detectable in the supernatant. To start, the 
optimized digestion conditions from the studies with the synthetic PSGL-1 active site peptide 
and with the recombinantly expressed PSGL-1 protein will be used. However, I anticipate a 
higher concentration of enzyme and longer digestion time may be needed in the experiments 
with neutrophils for two reasons: Cells have a much lower diffusion rate than proteins or 
peptides, therefore the probability of bromelain-neutrophil interactions will be lower, and since 
bromelain is able to cleave many different proteins on the cell surface, I suspect it will take 
longer to cleave cell surface-bound PSGL-1, compared to the solution-phase protein or peptide. 
After treating neutrophils with bromelain, the neutrophils will be pelleted at a speed that causes 
minimal damage to the cells (to prevent cell lysis and membrane disruption) but also is sufficient 
for the removal of the majority of cellular components from the supernatant. Following 
centrifugation, the supernatant will be removed and prepared for LC/MS analysis. 
The sample preparation stage will be critical to the success of the LC/MS analysis. The 
supernatant will be run though a molecular weight cut-off filter (5 kDa) to remove high-
molecular weight proteins and peptides that are not of interest to the analysis and that could clog 
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the chromatography column. Next, the salts will need to be removed from the sample by 
performing a standard procedure for trichloracetic acid precipitation of proteins and peptides 
from the solution.8 Following several rinse steps, the peptide will be resuspended in an 
appropriate mobile phase.  
Finally, numerous aspects of the LC/MS analytical method will need to be optimized. 
These include the contents of the mobile phase, flow rate, and column type and size, as well as 
the voltage for sample ionization. The goal in optimizing these parameters will be to allow 
sufficient separation of the various components in the samples to achieve efficient sample 
ionization and obtain a clean MS spectrum for each time-resolved LC peak.  
I expect that knowledge from prior mass spectrometry analyses of bromelain-treated 
recombinant PSGL-1 and bromelain-treated synthetic peptide will help us optimize the 
conditions for the analysis of the cell supernatant from bromelain-treated neutrophils. If it is 
known where bromelain cleaves PSGL-1, solid-phase synthesis can be used to synthesize the 
peptide fragment and the peptide can be run on LC/MS to determine what time it elutes. Then 
when the cell supernatant is run on the LC/MS, the elution time of the expected peptide fragment 
can be anticipated in order to collect MS data on that peak. If the peak for the PSGL-1 peptide 
fragment is time-resolved, it will also be possible to use standards of the pure PSGL-1 fragment 
to create a calibration curve that can be used to quantitatively determine the peptide levels in the 
supernatant. Overall, these studies will help us confirm, at a molecular level, how bromelain is 
acting upon PSGL-1 expressed on primary neutrophils in vitro.  
5.2 A more physiologically relevant model system: How does bromelain affect neutrophil 
recruitment to cytokine-stimulated endothelial cell monolayers? 
During an immune response, dying cells and bacteria secrete chemicals, such as 
cytokines that stimulate the endothelial lining of the blood vessel. Cytokine stimulation causes 
the endothelial cells to express P-selectin and E-selectin, among numerous other biomolecules 
that participate in the leukocyte adhesion cascade (Scheme 1.1).9  
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For decades, researchers have isolated and cultured human umbilical vein endothelial 
cells (HUVECs, Figure 5.2) for biological studies—in fact, most of the current understanding of 
the functioning of human endothelial cells is derived from experiments with cultured HUVECs.10 
A portion of these experiments have been applications of HUVECs in leukocyte flow assays with 
parallel-plate flow chambers.10 In the work described in Chapters 3 and 4, I used parallel-plate 
flow chambers to study leukocyte interactions with substrates presenting proteins, P-selectin or 
E-selectin, which are responsible for the initial tethering and rolling of leukocytes to the 
inflamed endothelium. The advantage of using photochemistry to generate substrates for 
leukocyte flow assays is the ability to immobilize multiple components and control the density of 
biomolecules presented. Leukocyte flow assays with substrates generated in this manner can 
assess the unique role that the individual components play in the process of leukocyte rolling. 
The primary shortcoming of using this method for generating biomolecular substrates that serve 
as models of the blood vessel, however, is that such substrates present proteins in a non-native 
context and in a highly simplified environment. In other words, a protein that is chemically 
 
Figure 5.2  Cytokine-stimulated monolayers of human umbilical vein endothelial cells 
(HUVECs) will be used as a model of the inflamed endothelium in future neutrophil flow 
assays. Scale bar: 30 μm. 
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attached to a surface will appear very different to leukocytes than a protein presented on the 
surface of endothelial cells in a blood vessel. 
Experiments on HUVECs have yielded a wealth of information regarding the effect of 
cytokine stimulation on the expression of biomolecules involved in the leukocyte adhesion 
cascade, including P-selectin,9a,11 E-selectin,9a,11c,12 ICAM-1,13 and VCAM-1.11b Of greatest 
relevance to these studies, numerous reports show the use of HUVECs as a model of the 
inflamed endothelium in flow assays with leukocytes.14 By using a parallel-plate flow chamber 
in conjunction with cytokine-stimulated HUVECs, researchers have studied leukocyte rolling 
and adhesion under conditions of physiological shear stress, with a substrate that is a more 
physiologically similar to the inflamed endothelium than simple biomolecules attached to a 
surface. Arguably, the most physiologically relevant environment is that which is inside a live 
animal, but while in vivo studies have been of enormous utility to the current understanding of 
the inflammatory response, they are limited by the lack of ability to control various experimental 
parameters, such as vessel diameter and flow rate. By using HUVECs for in vitro leukocyte flow 
assays, researchers strike a balance between physiological accuracy and experimental control. 
Previous studies have shown that certain inflammatory mediators cause specific proteins 
to be upregulated without affecting the expression of others. More specifically, histamine-
stimulated HUVECs have been found to upregulate P-selectin expression while E-selectin 
expression is unaffected,14a and studies in rabbit models of inflammation suggest that stimulation 
with IL-1β causes an upregulation in E-selectin expression without affecting P-selectin levels.15   
These previous research studies suggest that it may be possible to independently control 
the expression P-selectin and E-selectin, the two endothelial-expressed selectins responsible for 
leukocyte tethering and rolling, on cultured monolayers of HUVECs. Given this ability, I 
envision that one could extend the in vitro studies on the role of bromelain treatment on selectin-
mediated neutrophil recruitment to substrates presenting cytokine-stimulated HUVECs, which 
are more physiologically relevant than proteins immobilized on glass substrates. 
One could carry out the following experiments with cultured HUVECs. First, it will need 
to be confirmed that given the reported conditions, HUVECs can independently upregulate either 
P-selectin or E-selectin through cytokine stimulation with histamine or IL-1β, respectively. 
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HUVECs will be cultured to confluency in a 96-well plate. At 2 days post-confluency, cells will 
be stimulated for 24 hours in the presence of 20 ng/mL of IL-4 or TNF-α. Following stimulation, 
cells will be fixed, blocked, and stained with fluorescently labeled antibodies that recognize P-
selectin or E-selectin. The following controls will be performed: unstimulated cells will be 
stained with fluorescently labeled antibodies against P-selectin and E-selectin, and histamine- or 
IL-1β- stimulated cells will be stained with fluorescently labeled isotype control antibodies to 
account for nonspecific antibody binding. Data will be analyzed to confirm that histamine 
upregulates P-selectin independently of E-selectin, and IL-1β upregulates E-selectin 
independently of P-selectin. 
Once it is confirmed that cytokine stimulation upregulates P-selectin or E-selectin in the 
expected manner, HUVECs will be cultured in 35-mm culture dishes and use the same 
conditions used in the 96-well plate assays to stimulate cells to express P-selectin or E-selectin. 
Then neutrophils will be isolated from whole blood, characterize them for purity and viability, 
and use them in leukocyte flow assays to determine the role of bromelain treatment on the ability 
of neutrophils to tether to and roll on stimulated HUVECs. In preparation for leukocyte flow 
assays, neutrophils will be treated with bromelain or buffer, as described in Chapter 4. Briefly, 
neutrophils will be incubated for 30 min at 37 °C in 50 μg/mL bromelain in HBSS with Ca2+ and 
Mg2+, or in HBSS buffer alone. Cells will be rinsed, pelleted, and resuspended in HBSS with 
Ca2+ and Mg2+ and 0.5% human serum albumin (HSA) at 0.5 E 6 cells/mL. A 35-mm circular 
parallel plate flow chamber will be assembled with the 35-mm culture dishes containing 
cytokine-stimulated HUVECs.  Neutrophils will be introduced into the chamber with the flow 
rate at a predetermined flow rate that will be controlled by a syringe pump. Videos of neutrophils 
interacting with HUVECs will be recorded and analyzed using ImageJ software to determined 
the number of new tethers formed per unit time and area. The fully processed data will be 
compared to the results from Chapter 4’s flow assay studies that involved the use of 
benzophenone-immobilized P-selectin and E-selectin substrates, to see if the same trends are 
observed in both sets of data.  
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5.3 Biomolecular gradient studies: How do neutrophils process solution-phase and surface-
bound biomolecular signals simultaneously in vitro? 
 My previous studies on the leukocyte adhesion cascade have focused on the first step of 
the process: selectin-mediated tethering and rolling, and on the effects that bromelain treatment 
has on the ability of leukocytes to be recruited to surfaces presenting immobilized P-selectin and 
E-selectin. Another interesting component of leukocyte recruitment that is still not completely 
understood is the process of cell migration to the site of infection in response to immobilized and 
soluble-phase cues. The process of cell migration has been previously studied involving both 
leukocytes16 and other adhesive cells.1,17 
 
 A traditional approach to studying leukocyte migration in response to chemokines 
involves the use of Transwell migration assays. Cells are placed inside a well whose base is 
composed of a permeable membrane (Figure 5.3). The well is placed inside a solution containing 
 
Figure 5.3  Schematic representation of a Transwell migration assay. Cells are suspended in 
solution in the absence of chemokine and placed in a well which has a permeable membrane 
base. Over time, cells are observed to migrate through the membrane in response to the 
soluble chemokine gradient. 
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a cytokine, and cells respond by moving in the direction of the higher concentration of cytokine 
and migrate through the membrane. The extent of migration is characterized by determining the 
number of cells that transmigrated through the permeable membrane.16b Transwell migration 
assays have been used by researchers to study the effect of bromelain treatment on the ability of 
neutrophils to migrate in response to two different chemotaxis-inducing molecules, a bacterial 
peptide formyl-Met-Leu-Phe (fMLP) and IL-8, showing that bromelain treatment abolishes 
migration in response to IL-8 but not fMLP.16b 
 The Transwell migration assay, due to the relative ease of the experiment, is a good 
starting point for basic studies on cell migration in response to biological cues. The primary 
limitation of the Transwell assay, however, is that it does not present the cells or the cues in a 
physiologically relevant setting. For example, a prerequisite to cell migration through the 
extracellular matrix (ECM) is the ability of the migrating cell to adhere to ECM proteins—this is 
true of both adhesive cells and leukocytes.18 But in a Transwell assay, cells are suspended in a 
solution, and the mechanism by which the cells migrate through the permeable membrane in 
response to soluble cues is independent of adhesion to ECM proteins, and therefore not 
representative of the mechanism by which cells undergo chemotaxis in a physiological 
environment. 
 In an effort to improve upon the Transwell migration assay, researchers have turned to 
hydrogels, Matrigel, and collagen matrices, each composed of cross-linked biological 
polymers.19 For example, a protein gradient can be made in a three-dimensional collagen matrix 
by placing two reservoirs, one with protein solution and the other with buffer or a second protein 
component, on each site of the hydrogel. The resulting solution-phase gradients presented within 
the hydrogel can be used to study cell migration in response to soluble gradient cues.20 It is 
possible to generate immobilized gradients of proteins within a hydrogel construct by tailoring 
the hydrogel to present a photochemical crosslinker, such as benzophenone, creating a solution-
phase gradient within the hydrogel, and then using light to immobilize the solution-phase 
gradient to the hydrogel.19b In this way, hydrogels have been demonstrated to be applicable to 
probing migration in response to both soluble and immobilized cues. 
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 A third approach to studying cell migration utilizes microfluidics to generate a solution-
phase gradient of biomolecules. In some demonstrations, the solution-phase gradients are 
converted into immobilized gradients by using a surface chemistry tethering approach, such as 
EDC/NHS coupling.21 Other approaches, such as electrochemical desorption,22 photochemical 
deprotection,23 and diffusion-guided surface adsorption24 have also previously been used to 
generate surface-immobilized gradients for applications in cell biology. It is also possible to 
generate solution-phase gradients through diffusion16g or through the use of microfluidic gradient 
generation devices.25 These demonstrations of solution-phase gradient generation with 
microfluidics are part of the necessary groundwork for studying the interplay between 
immobilized biomolecules and solution-phase gradients.  
 
Figure 5.4  Schematic of microfluidic gradient generation device that will be used to create a 
solution-phase gradient. Adherent cells will be observed under a microscope to see if they 
migrate in response to the soluble gradient, and the effects of bromelain on cell adhesion and 
migration will be investigated. Adapted from reference.1 
Flow
Observe cell 
polarization 
and migration in 
response to soluble 
gradient cues
109 
 
I envision that one could couple the methodology I developed for the generation of 
immobilized gradients with microfluidic gradient generation to study the interplay between 
immobilized biomolecular signals and soluble biomolecular signals (Figure 5.4). I could generate 
a surface-immobilized biomolecular gradient on a BP-modified substrate and then assemble the 
substrate with a microfluidic device that will allow the introduction of a solution-phase 
gradient25c on top of the immobilized gradient. 
 As a proof-of-concept demonstration of the technique, one could generate BP-modified 
substrates presenting immobilized fibronectin. After allowing neutrophils to adhere to the native 
ECM protein, the substrate will be rinsed to remove non-adherent neutrophils and assemble the 
substrate with a microfluidic gradient generation device. A one-component solution-phase 
gradient of fMLP or IL-8 will be generated over the immobilized neutrophils, and time-lapse 
microscopy will be used to visualize the migration of neutrophils in response to each individual 
biomolecular cue. To assess the effect of bromelain treatment on the ability of neutrophils to 
both adhere to fibronectin and migrate in response to fMLP or IL-8, neutrophils will be treated 
with bromelain before seeding them onto fibronectin substrates. In contrast to the Transwell 
migration assays that have been previously reported to assess the affect of bromelain treatment 
on migration in response to fMLP and IL-8,16b this new approach will take into consideration that 
under physiological conditions, migrating cells must first adhere to ECM proteins before they 
undergo polarization in response to chemotactic molecules. These initial studies could lead to a 
better understanding of the mechanism underlying bromelain’s anti-inflammatory properties by 
assessing the effect of bromelain treatment on neutrophil adhesion and subsequent migration in 
response to inflammatory signals.. 
 Following these studies, one could perform experiments combining solution-phase and 
immobilized biomolecular gradients to determine the effect of presenting a cell with both 
immobilized and solution-phase gradients of chemotactic molecules. A substrate presenting a 
uniform density of fibronectin will be generated and an overlapping immobilized gradient of IL-
8 or fMLP. These substrates will be characterized with fluorescence analysis as described in 
Chapter 2. The microfluidic setup will then be used to create a solution-phase gradient of fMLP 
or IL-8, either in the same direction as the immobilized gradient, or in the opposite direction. 
Subsequent cell adhesion and migration studies will reveal if adherent neutrophils migrate at a 
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faster rate in the presence of both a solution-phase and immobilized gradient. In the case of the 
opposing gradients, the studies will reveal which of the two types of gradients—the solution-
phase or immobilized—is able to out-compete the other to cause cells to migrate in one direction 
or the other. These studies will help shed light on the interplay between solution-phase and 
immobilized biomolecular cues during leukocyte migration.  
Dual-gradient experiments can also be extended to study the effects of bromelain on 
neutrophil adhesion and migration. Experiments will be performed with substrates presenting 
fibronectin plus an immobilized fMLP or IL-8 gradient in the absence of a solution-phase 
gradient, and with substrates presenting fibronection in the presence of a solution-phase fMLP or 
IL-8 gradient only. These studies will help determine if bromelain’s ability to reduce migration is 
dependent on the nature of the biomolecular gradient (solution-phase vs. immobilized). Data 
from these experiments will assist in the design of additional in vitro experiments on bromelain’s 
effects on cell migration in response to biomolecular cues. 
5.4 Conclusion 
 The proposed work described in this chapter will serve to elucidate the molecular details 
underlying bromelain’s effects on various aspects of the leukocyte adhesion cascade, and will 
also shed light on the interplay of multiple biomolecular cues on neutrophil adhesion and 
migration. All in all, the photochemical methodology for the generation of biomolecular 
interfaces, in conjunction with the future work described in this chapter, will result in a better 
understanding of bromelain’s mode of action and will lay the groundwork for the development of 
more effective anti-inflammatory treatments. 
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